Role of innate cellular immunity in the immunopathogenesis of HIV-1 infection in Uganda by Sekiziyivu, Proscovia Naluyima
R
IN
 
D
OLE 
 THE 
CENTE
EPART
Karoli
OF IN
IMMU
INF
R FOR 
MENT O
nska Inst
NATE
NOP
ECTIO
Proscovia
St
INFECT
F MED
itutet, St
 CEL
ATHO
N IN
 Naluyim
ockholm 
IOUS M
ICINE, H
ockholm
LULA
GEN
 UGA
a Sekiziyi
2016 
EDICIN
UDDIN
, Sweden
R IM
ESIS 
NDA 
vu 
E 
GE 
 
MUN
OF H
 
ITY 
IV-1 
 All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by Eprint AB 2016 
© Proscovia Naluyima Sekiziyivu, 2016 
ISBN 978-91-7676-453-4 
Role of Innate Cellular Immunity in the 
Immmunopathogenesis of HIV-1 infection in Uganda 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
By 
Proscovia Naluyima Sekiziyivu 
Principal Supervisor: 
Prof. Johan K. Sandberg 
Karolinska Institutet 
Department of Medicine, Huddinge 
Division of Center for Infectious Medicine 
 
Co-supervisor(s): 
Dr. Michael A. Eller 
US Military HIV Research Program 
Walter Reed Army Institute of Research 
MHRP Flow Cytometry Laboratory 
 
Prof. Fred Wabwire-Mangen 
Makerere University 
College of Health Sciences 
Makerere University Walter Reed Project 
Opponent: 
Prof. Clive Gray 
University of Cape Town, South Africa 
Department of Clinical Laboratory Sciences 
Division of Immunology 
 
Examination Board: 
Prof. Francesca Chiodi 
Karolinska Institutet 
Department of Microbiology, Tumour and Cell 
Biology 
 
Prof. Jorma Hinkula 
Linköping University 
Department of Clinical and Experimental 
Medicine 
 
Prof. Karin Loré 
Karolinska Institutet 
Department of Medicine, Solna 
 
 
 

 
“Today it's me 
Tomorrow someone else 
It's me and you 
We've got to stand up and fight 
We'll shed a light in the fight against AIDS 
Let's come on out 
Let's stand together and fight AIDS” 
Lyrics to ‘Alone and Frightened’ by Philly Bongoley Lutaaya 
 
 
 
It is the glory of God to conceal a thing: but the honor of kings is to search out a matter. 
Proverbs 25:2, The Bible, King James Version 
 
 
 

  
ABSTRACT 
The global epidemic of HIV has resulted in more than 34 million deaths and currently 36.9 
million HIV-infected people worldwide. Uganda has an HIV prevalence of 7.3%, equating to 
about 1.6 million people. This has placed enormous pressure on the social, economic and 
medical structure of society. HIV is phylogenetically diverse, with HIV-1 subtypes A, B and 
C accounting for ≥70% of infections globally. While HIV-1 subtype C confers the worst 
prognosis for a patient, it is closely followed by subtype D which, together with subtype A, 
accounts for ≥90% of HIV infections in Uganda. HIV infection is associated with rapid viral 
replication, concomitant inflammation and immune activation, and massive CD4 T cell loss, 
which all together contribute to morbidity and eventual death. Although antiretroviral therapy 
lowers viral load and improves CD4 T cell recovery in chronic infection, it does not fully 
eliminate chronic immune activation nor restore immune function, resulting in non-AIDS 
related morbidity. Additionally, despite great effort, a preventive or therapeutic vaccine is yet 
to be developed. 
Studies in chronic untreated HIV-1 infection may shed more light on correlates of immune 
protection that may be utilized to develop effective preventive or therapeutic vaccines or 
drugs. The innate immune system, as the first to encounter the HIV virus upon exposure and 
infection may be critical in directing immune responses that can prevent, attenuate or cure 
infection. In this thesis I aimed to study the role of the innate cellular immunity in the 
immunopathogenesis of HIV-1 subtype A and D infection in Uganda. In Paper I, using 
whole blood from healthy blood bank donors, we established normal lymphocyte reference 
ranges for Ugandans and showed demographic differences that may influence immune 
responses to disease and vaccination. Additionally, utilizing cryopreserved peripheral 
mononuclear blood cells from chronic untreated HIV-1 infected persons we studied the 
phenotypes and function of natural killer cells, unconventional T cells and regulatory T cells 
plus their roles in HIV-1 infection (Papers II-IV). Here we found both HIV-associated 
immune dysregulation of multiple cellular subsets and expansion of a previously little 
described innate-like terminally differentiated CD8 T cell subset. Furthermore, in Paper V 
we describe demographic differences in biomarkers of inflammation that not only associate 
with disease progression, but also expand our knowledge of HIV-related gut dysbiosis. Thus, 
the data presented here provides more insight into HIV-driven immune dysfunction, subtype-
related immunopathogenesis, and demographic differences that add to the body of knowledge 
concerning HIV infection.   
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1 HIV-1/AIDS 
1.1 Overview 
It is now close to 35 years since the first cases of the acquired immune deficiency syndrome 
(AIDS) were first described in five homosexual men in the United States 1. In the beginning, 
doctors from different parts of the world described patients presenting with aggressive and 
rare infections and cancers that resisted most forms of medication. Within a few years it had 
become clear that these were a collection of syndromes that resulted from generalized 
immune deficiency arising from infection with a yet to be identified agent. In 1983, 
Francoise Barré-Sinoussi and Luc Montagnier identified the causative agent of AIDS 2 that 
was later described to preferentially infect 3, 4 and cause loss of CD4 T cells 5, and was 
named human immunodeficiency virus (HIV) 6.  
 
Uganda is an East African country with a population of over 34 million people 7, of whom 
approximately 1.6 million are living with HIV 8. Here, the first cases of AIDS were noticed in 
the south western district of Rakai (Figure 1) in 1982, and fully described by Serwadda et al. 
in 1985 9. These were atypical in that rather than the generalized lymphadenopathy and 
aggressive Kaposi’s Sarcoma seen in patients in western countries, Ugandans presented with 
extreme weight loss and diarrhoea occasioning the local name ‘Slim disease’, but with the 
immune deficiency recognised by anergy to most skin tests. Epidemiological comparisons 
later showed that this was the presentation of AIDS among Africans 10. In 1986, Clavel and 
co-workers isolated another retrovirus from West African patients with symptoms similar to 
Slim disease that was different from the HIV virus 11; through molecular cloning it was 
shown to be related to HIV, but with a different genomic sequence 12. This led to the 
designation of the virus causing most infections globally as HIV-1, and the less prevalent 
West African type HIV-2. 
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losses in productivity, and disruption of family structure. The effects on the economy led to a 
cycle of poverty that increased risky behaviour such as prostitution and cross-generational 
sex, thus increasing the risk of acquiring the infection. Health systems were ill-equipped to 
handle the influx of severely ill patients, both by numbers and complexity of the disease. 
Amid all this it became clear that HIV infection in Africans, while sharing many similarities 
with that in the western world, had significant differences that accentuated the effects of the 
disease at the individual and population level. 
 
1.3 HIV virology 
Phylogenetic studies have shown that HIV, a retrovirus of the lentivirus family 41, originated 
from several zoonotic events between non-human primates (NHPs) and humans, in 
Cameroon and the Democratic Republic of Congo (reviewed extensively in 42, 43). The two 
major lineages of HIV, HIV-1 and HIV-2, originated from independent transmission events 
to humans, have multiple groups within each, and have undergone further rapid gene 
mutation and recombination in the human population due to extensive virus-host interaction 
(reviewed in 44). Based on sequence similarity HIV-1 strains are classified into groups M 
(which is responsible for the HIV pandemic), N, O and P. HIV-2 has groups A-H, and is 
largely restricted to West Africa. HIV-1 group M is subdivided into subtypes A, B, C, D, F, 
G, H, J and K, and is widely distributed thorughout the world (Figure 2), particularly in 
Africa where subtypes A, C, D and CRF02-AG account for over 80% of infections (reviewed 
in 45). Globally, the most prevalent HIV subtypes are A, B, and C with subtype C most 
predominant. In addition, there are a large number of circulating recombinant forms (CRFs) 
and unique recombinant forms of HIV-1.  
 
  
Figure 2
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1.4 HIV-1 disease, treatment and prevention 
During acute infection the HIV virus infects and replicates in a cell over a period of up to 48 
hours 52, producing over 104 virions per cell 53. New virions and infected cells spread 
systemically from mucosal layers to lymphoid tissues 54 (reviewed in 55). This is accompanied 
by an exponential increase in viral replication to peak viremia, that decreases to a steady-state 
viral load, also called set point viral load 56, which signifies the end of acute and beginning of 
chronic infection and is a prognostic marker for AIDS (reviewed in 57). Concomitantly with 
the first rise towards peak viremia there is rapid increase in innate proinflammatory cytokines 
such as interferon alpha (IFNα), interleukin-15 (IL-15), tumor necrosis factor (TNF), IFNγ, 
IL-6 and IL-18, and chemokines such as monocyte chemotactic protein (MCP-1) and 
inducible protein 10 (IP-10), to stimulate immune responses 58. This is followed by an 
increase in the immunoregulatory cytokine IL-10, in an attempt to dampen the immune 
response. Acute HIV infection is also characterized by a massive loss of CD4 T cells that 
begins within days of infection 59, particularly from the gut-associated lymphoid tissue 60, by 
NK cell-mediated killing 61, HIV-driven up-regulation of apoptotic molecules and subsequent 
apoptosis 62-64 (reviewed in 65), and directly through DNA-dependent protein kinase 66; and 
increasing and persistent direct and bystander immune activation 67, 68, known to be one of the 
major causes of HIV pathogenesis (reviewed in 69, 70). This leads to a generalized 
immunodeficiency 2, 5 manifest particularly in low CD4 T cell counts 3, 4, and impaired host 
immunity to a variety of opportunistic infections 20. The quantity of HIV-1 RNA in plasma, 
reflective of ongoing viral replication, has been found to correlate inversely with the CD4 T 
cell counts and directly correlates to HIV-1 disease 71. The quantitative competitive 
polymerase chain reaction (QC-PCR) is a sensitive and accurate assay for the monitoring of 
plasma viral load in patients at all stages of infection 72. Plasma viral load is now routinely 
used in the healthcare and clinical management of HIV infection. 
 
The description of the HIV-1 replication cycle inspired scientists to develop antiretroviral 
drugs to block or counteract specific aspects of viral entry and replication. The first 
successful drug, azidothymidine (zidovudine), was associated with significant decreases in 
mortality and frequency of opportunistic infections 38, reduction in viral load, and 
improvement in CD4 T cell counts, but with significant toxicity 73 and incomplete viral 
clearance. It quickly became clear that the virus mutates rapidly to become drug resistant 74 
and suggestions were made to develop a multiple-drug strategy 75. Approaches utilizing a 
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combination of at least three drugs, each targeting a different aspect of the replication cycle, 
revolutionalized HIV treatment by lowering viral load to undetectable levels and markedly 
improving life expectancy 76, 77. This is known as highly active antiretroviral therapy 
(HAART).  
 
Further studies showed that initiating antiretroviral therapy (ART) earlier improves prognosis 
by preventing CD4 T cell loss, preserving gut and lymph node structure, as well as arresting 
aberrant immune activation 60, 78-80. Thus the latest WHO treatment guidelines recommend 
ART for all HIV-1 infected persons with a CD4 T cell count ≤500 cells/mm3 of blood 
regardless of plasma viral load 13. In addition to improving quality of life of HIV-1 infected 
persons, the WHO has recommended the use of ART to reduce the risk of HIV transmission 
from an infected person to an uninfected individual, as well as pre-exposure prophylaxis 
(PrEP) to protect most at risk vulnerable populations from HIV acquisition 13. When taken 
within 72 hours of exposure ART protects against establishment of infection (termed post-
exposure prophylaxis – PEP). ART is also successfully used to prevent transmission of HIV 
from mother to child (eMTCT). 
 
Despite all this progress, there are still hurdles to overcome. Only about 50% of HIV-infected 
people eligible for ART are on treatment 81; by 2013, only 40% of HIV-infected Ugandans 
eligible for ART were on treatment 8, and yet this is one of the three countries contributing up 
to 48% of new infections in sub-Saharan Africa 82. It is noteworthy that immunopathogenesis 
differs according to infecting HIV type. Much fewer people infected with HIV-2 go on to 
develop AIDS when compared to HIV-1 83 (reviewed in 84), despite up to 60% homology in 
amino acid sequence of the viral genome 84. Within HIV-1 group M, subtype C (globally 
most prevalent strain) and D (prevalent in East Africa) appear to confer worse prognosis as 
regards time to development of AIDS and death 85-87, CD4 T cell loss (reviewed in 88, 89) and 
treatment failure 90, yet it is not clear why. In addition, the immune system does not fully 
restore to its pre-HIV state even after long-term HAART, thus patients go on to develop non-
AIDS related comorbidities that compromise their well-being and life expectancy (reviewed 
in 91-93). 
 
The ultimate solution would be to totally prevent/protect from acquisition of HIV. 
Behavioural interventions such as abstinence, being faithful to one partner and use of 
condoms, while having significant effects in reducing HIV incidence, can for various reasons 
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not totally eliminate transmission. Other strategies, such as medical male circumcision, while 
successful in preventing HIV acquisition in up to 66% of males 94, have faced many 
challenges particularly due to resource constraints in the most affected countries 95. Several 
HIV vaccine products and microbicides have been tested globally with little to no success 
(reviewed in 96 97). The exception is the RV144 phase III vaccine trial conducted in Thailand 
that showed a modest protection of 31% in the HIV-uninfected who received the vaccine 98, 
though that was not good enough for public health purposes. The biggest challenge to these 
efforts has been lack of clarity on an immune correlate of protection 97, although indepth 
analysis of data from the RV144 trial have begun to provide important clues 99. It is 
increasingly believed that a single program may not prove effective, and that a combination 
of prevention strategies will be needed to radically reduce or eliminate HIV transmission in 
the human population 100. In the meantime though, it is important that research on both 
treated and untreated HIV infection continues so as to identify ways of improving the 
prognosis of patients, and better understanding of correlates of protection that can guide 
vaccine design. 
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2 THE IMMUNE SYSTEM 
2.1 Overview 
The earth houses approximately 7.3 billion people 101 as of 2015, in addition to other forms of 
life such as plants, animals and, importantly, microorganisms such as bacteria, viruses and 
fungi. This ecosystem requires that organisms form relationships so as to efficiently utilize 
resources, although some (relationships) end up being detrimental to one of the organisms. 
The immune system is a network of cells, tissues, chemicals or proteins designed to protect 
living organisms from microbial attack from microorganisms, while at the same time 
maintaining self-tolerance to avoid autoimmunity. It is bimodal in nature, having an innate 
and adaptive arm, with both cellular and humoral (antibody) components and, as a basic 
principle, distinguishes foreign antigen from self.  
 
2.2 The innate immune system 
The innate immune system is tasked with initial identification, protection and/or 
neutralization of antigen, as it recognizes a vast array of molecular patterns quickly and is 
highly developed in its ability to discriminate self from non-self. The simplest form of 
defense is the anatomical barrier, akin to a wall around a city, meant to define the perimeter 
of the individual and block foreign organisms from entering. The skin is the biggest of 
these organs but others include the mucosal surfaces in the mouth, airways, intestines, and 
genital tracts, which secrete antimicrobial peptides and chemicals plus mucus for defense. 
The innate immune system involves a complex recognition system where cells and tissues 
have germ line-encoded pattern recognition receptors (PRRs) that detect (1) foreign antigen 
in the form of pathogen associated molecular patterns (PAMPs) that are conserved through 
evolution of classes of bacteria, viruses, and some fungi and parasites, and (2) self-antigen 
in the form of stress molecules, misplaced proteins and chemicals, otherwise known as 
damage-associated molecular patterns (DAMPs) (reviewed in 102 103). The PRR-
PAMP/DAMP complex activates intracellular signaling pathways that trigger 
proinflammatory and antimicrobial responses, involving molecules such as phosphatases, 
kinases and transcription factors (reviewed in 102). This in turn leads to rapid production of 
molecules such as cytokines and chemokines, and the expression of receptors and cell 
adhesion molecules required to present and neutralize the antigen through activation of the 
complement cascade, phagocytosis, cytotoxic killing and/or activation of the adaptive 
immune system. Note that some innate immune cells display memory generated by 
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epigenetic reprogramming during the initial response, and that results in a heightened 
response that is nonspecific and antigen independent 104 – known as trained memory. 
Typical innate immune cells include granulocytes (neutrophils, eosinophils and basophils), 
antigen-presenting cells (APCs) such as dendritic cells, macrophages and innate lymphoid 
cells that include natural killer (NK) cells. NK cells are one of two major focuses of this 
thesis. 
 
2.2.1 Natural killer cells 
NK cells are innate lymphoid cells first described for their killing of tumor and virus-infected 
cells 105, 106. They develop from a common lymphoid progenitor into large granular 
lymphocytes constituting up to 15% of all peripheral blood lymphocytes and have two main 
subsets, classified according to their expression levels of CD56 (neural cell adhesion 
molecule 1; NCAM): CD56bright immature NK cell subset 107 and the CD56dim mature subset 
that constitutes about 10% and 90% of peripheral blood NK cells, respectively (reviewed in 
108-111). CD56bright NK cells mature and differentiate towards CD56dim through a sequential 
loss and gain of multiple surface receptors 112, 113 in an IL-15 dependent manner, through the 
action of the transcription factors nuclear factor, interleukin 3 regulated (NFIL3), T-box 
expressed in T cells (T-bet) and eomesodermin (Eomes) (reviewed in 114). It should be noted 
that NK cells can also develop in both secondary lymphoid and non-lymphoid tissues 
(reviewed in 115), and that IL-15 is required for their maintenance 116. 
 
NK cells utilize germ-line encoded killer-cell immunoglobulin-like receptors (KIR) to 
recognize targets, some of which are activating and others inhibitory (reviewed in 117). Other 
activating NK receptors include natural cytotoxicity receptors (NCRs: NKp30, NKp44, 
NKp46, NKp80), C-type lectin receptors (NKG2C, NKG2D, NKG2E), adhesion molecules 
(DNAM-1), PRRs (Toll-like receptors – TLRs), while NKG2A is inhibitory. The major KIR 
ligands are MHC class I molecules, expressed by majority of cells in the host, and act to 
inhibit NK cell cytotoxicity. Absence of MHC class I – known as ‘missing self’ and often 
observed in virus-infected or cancerous cells – abrogates inhibition and thus results in NK 
cell activation (reviewed in 118). The expression of NK cell receptors is dependent on antigen 
experience 119 and tissue environment 120 and varies from cell to cell. The strength of 
activation induced by binding of receptors also varies from cell to cell, a feature that is 
utilized in NK cell education: inhibitory receptor binding to self MHC during development is 
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used to tune the NK cell against auto-reactivity while maintaining recognition and reactivity 
to infected or malignant cells (reviewed in 108, 109, 121). This is important, as NK cells are 
constitutively primed to kill targets without prior engagement through (1) exocytosis of 
cytolytic granules (perforin perforates the target cell and granzymes induce apoptosis) or (2) 
death receptors. They also modulate immune responses through the production of cytokines 
such as interferon gamma (IFNγ) and tumour necrosis factor (TNF), and β chemokines such 
as macrophage inflammatory protein (MIP)-1 alpha (MIP-1α; CCL3), MIP-1β (CCL4) and 
RANTES (CCL5) 122. These cytokines and chemokines are crucial in directing the adaptive 
immune response to viral infection 123, 124. On the other hand some chronic viral infections 
such as cytomegalovirus (CMV) epigenetically modulate NK cell expression of activating 
and inhibitory receptors, and signaling molecules, and thus alter the immune response 125, 126 
(reviewed in 127). It should be noted that NK cells may directly recognize pathogens through 
PRRs and kill them 128. 
 
NK cells also express a variety of cytokine and chemokine receptors and can thus be 
activated by the proinflammatory cytokines (IFNα, IL-2, IL-12, IL-15 and IL-18 129, 130, 
reviewed in 131) and ‘called’ to sites of infection and secondary lymphoid tissues by 
chemokines (CX3CL1, MIP-1α, MIP-1β, RANTES 132, 133), respectively, released by APCs. 
Through crosstalk between NK cells and DCs, this activation induces the mammalian target 
of rapamycin complex 1 (mTORC1) pathway 134(up regulating metabolic processes) leading 
to release of the antiviral cytokine, like IFNγ, that stimulates an antiviral state and activates 
dendritic cells to mature and present viral antigens (reviewed in 123, 135, 136). In addition, 
activation of NK cells leads to generation of a long-lived memory NK cell pool 137, 138 104, 139 
(reviewed in 140). Furthermore, IFNγ from NK cells mobilizes T cells to the appropriate areas 
of the lymph node for activation 141. 
 
CD56dim NK cells express FcγRIIIa, the activating low affinity type I Fc receptor (CD16) 
whose ligation to an antigen specific IgG that then binds antigen on target cell results in 
antibody-dependent cellular cytotoxicity (ADCC 142, 143). CD56bright NK cells do not express 
this receptor. In chronic viral infections a third NK cell subset, the CD56neg CD16+ NK cells, 
barely visible in the peripheral blood of healthy persons, expand 144. This subset is believed to 
represent exhausted CD56dim NK cells although the direct subset relationships and 
mechanisms involved are still not firmly established. Interestingly, although CD56neg NK 
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cells are less functional than CD56dim NK cells, they retain the ability to express chemokines 
145. It should be noted that in vivo activation of NK cells involves ligation of multiple of the 
aforementioned receptors, both activating and inhibitory plus chemokine receptors, adhesion 
molecules and TLRs, and requires a stronger activating than inhibitory signal to occur 110, 146. 
 
2.3 The adaptive immune system 
The adaptive immune response is delayed compared to the innate immune response and is 
triggered by recognition of antigen presented on major histocompatibility complex (MHC) 
receptors by APCs or target cells (reviewed in 147). Secondary stimuli that amplify the signal 
include either ligation of costimulatory receptors on T cells with their ligands on APCs, or 
cytokine activation, leading to activation, differentiation and proliferation of antigen-specific 
effector cells (reviewed in 148), and establishment of a life-long memory pool of cells that will 
respond very quickly and strongly to subsequent exposure. The adaptive immune system 
consists of two major cell types: T cells which develop in the thymus and B cells that develop 
in the bone marrow. T cells use a transmembrane protein T cell receptor (TCR) while B cells 
use a transmembrane B cell receptor (BCR) to recognize cognate antigen. Engagement of 
these receptors triggers intracellular signaling pathways and transcription factors that activate 
gene expression leading to maturation, differentiation and proliferation of the naïve cell. This 
process also leads to down-stream activation of effector programs in T cells with production 
of cytokines and chemokines, and killing of target cells. In B cells the major effector response 
is production of antigen-specific antibodies. The specificity of adaptive effector cells is 
dependent on gene-rearrangement by somatic recombination of the V, D and J segments of 
the β chain of the T cell receptor (reviewed in 149), and the heavy and light chains of the B 
cell immunoglobulin (B cell receptor) to create millions of unique possibilities of cell 
receptor specificities needed to detect a variety of potential antigens. Thus, the adaptive 
antimicrobial response is tailored towards a specific pathogen. T cells are a major focus of 
this thesis. 
 
2.3.1 Conventional T cells 
Naïve T cells are generated in the thymus and circulate between secondary lymphoid tissues 
and the periphery on the lookout for cognate antigen. They express the TCR in association 
with two other membrane-spanning receptors, the CD3 – a signal transduction complex 
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universally expressed on T cells – and glycoprotein co-receptor that can either be CD4 or 
CD8. CD4 and CD8 receptors bind extracellular portions of MHC class II or MHC class I 
respectively, recruit tyrosine kinases to the TCR complex and thus amplify the signal. MHC 
class I molecules present short peptides derived and processed from intracellular pathogens or 
stress molecules while MHC class II presents longer peptides processed from exogenous 
pathogens. The formation of CD3-TCR-CD4 or CD8 complex with cognate peptide-MHC 
complex presented by APCs leads to phosphorylation of the intracellular domains of the 
TCR/CD3 complex and activation of kinases such as SYK, LCK and ZAP70 that lead to 
downstream signaling and activation of transcription factors that result in activation of the T 
cell 150. This process is energy intensive and requires upregulation of metabolism to support 
the increased demand 151. It primes the T cell for differentiation into an effector cell in an IL-
2 dependent manner leading to clonal expansion and differential expression of chemokine 
and homing receptors that target cells in and out of peripheral compartments and secondary 
lymphatics. Once the infection has been cleared, the pool of effector cells contracts leaving 
some few that differentiate into long-lived memory cells that will be called upon on 
secondary challenge or antigen re-encounter 152, 153. Naïve T cells can also proliferate by way 
of homeostasis in response to the cytokines IL-7 and IL-15 (reviewed in 154) with the latter 
being important for maintenance of effector T cells 116, 155, thus ensuring a continuous supply 
even when the thymus contracts with age.  
 
T cell differentiation phenotypes are described by the expression patterns of multiple 
molecules such as cytokine, chemokine, integrin, homing and adhesion receptors, and are 
important in denoting localization and function of a particular cell (reviewed in 156). CD4 and 
CD8 T cells can be categorized according to the surface expression of CD45RA and CCR7 
157 (reviewed in 158-160), a receptor-linked protein tyrosine phosphatase crucial for signal 
transduction and thus cell activation (reviewed in 161), and a CC-chemokine receptor 
necessary for the homing of T cells to lymphoid organs and tissue, and motility therein, in 
response to chemokines CCL19 and CCL21 (reviewed in 141, 162), respectively. Naïve T cells 
are CD45RA+CCR7+, central memory T cells (TCM) are CD45RA-CCR7+, effector memory 
T cells (TEM) are CD45RA-CCR7-, terminally differentiated effector memory T cells 
(TEMRA) are CD45RA+CCR7-, while tissue-resident memory T cells (TRM) are CD45RA-
CCR7- that are CD69-/+CD103-/+ depending on location 157 (reviewed in 160). The T cell 
costimulatory molecule, Traf-linked tumor necrosis factor receptor family member CD27 is 
important for the generation of memory T cells (reviewed in 163, 164) as it amplifies 
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proliferation and enhances cell survival of antigen-specific T cells. It is therefore, together 
with CD45RA, also used to classify T cell subsets. 
 
It should be noted that the chemokines CCL3, CCL4 and CCL5 are important for recruiting T 
cells through ligands such as CCR5 into lymph nodes draining sites of inflammation for 
antigen-specific activation and differentiation into memory T cells 165, 166 (reviewed in 156). 
Beyond recruitment, CCR5 ligation influences T cell production of IL-2 and its dependent 
function inclusive of T cell proliferation 167. TCM circulate between blood and lymphoid 
tissue, TEM between blood and peripheral tissue, TRM remain in specific tissues, while 
TEMRA are found mainly in circulation. Naïve CD4 T cells, once activated in lymphoid 
tissue, differentiate into TCM, then into TEM that are thought to differentiate into TRM in 
mucosal, peripheral and lymphoid tissue by homeostasis or upon secondary stimulation. On 
the other hand, naïve CD8 T cells, once activated in lymphoid tissue, are thought to 
differentiate directly into either TEMRA or TEM, with the latter differentiating into TRM in 
mucosal, peripheral and lymphoid tissue by homeostasis or upon secondary stimulation. This 
provides a lifelong pool of polyfunctional antigen-specific rapid responders to infection. CD8 
T cells have recently been shown to differentiate, in the elderly, into a new subset of cells 
retaining a naïve phenotype but as polyfunctional as memory T cells (TMNP cells) in response 
to persistent infections 168. It should be noted that terminally differentiated cells undergo 
replicative senescence whereby they cease to proliferate but express high amounts of 
proinflammatory cytokines 169 due to the shortening of telomeres, in a bid to protect the host 
from cells that become increasingly dysfunctional (reviewed in 170). 
 
CD4 T cells are primarily helpers as they direct adaptive immune responses by activating 
other immune cells; influence innate immune responses; and perform antiviral functions 
through production of cytokines such as IFNγ and TNF, in addition to direct cytotoxic killing 
through perforin and granzymes (reviewed in 171). The nature and load of pathogen CD4 T 
cells encounter, APC involved, and resulting inflammatory milieu stimulates distinct 
transcription factors, affects the phenotype and function the cells adopt 172 and determines the 
subset a naïve CD4 T cell differentiates into (reviewed in 171, 173). Type 1 helper T (TH1, 
transcription factor T-bet) cells develop in the presence of high levels of pro-inflammatory 
cytokines such as IFNγ, IL-12 and type I IFNs and primarily produce IFNγ. TH2 cells develop 
in the presence of IL-4 and primarily produce IL-4, IL-5 and IL-10 (transcription factor 
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GATA-3). TH17 cells develop in the presence of IL-6 and TGFβ and primarily produce IL-
10, IL-17 and IL-21 (transcription factor RORγt). TFH (T follicular helper, transcription factor 
BCL-6) cells develop within B cell follicles in the presence of IL-6 and IL-21 and primarily 
produce IL-4 and IL-21. Regulatory T cells (Tregs, transcription factor FOXP3) develop in 
the presence of TGFβ but without IFNγ, IL-4 and IL-6, and primarily produce the anti-
inflammatory cytokines IL-10, TGFβ and IL-35. 
 
Memory CD4 T cells enhance immune responses on secondary challenge or reinfection by 
rapidly activating innate immune responses through their production of proinflammatory 
cytokines, chemokine-driven recruitment of antigen-specific cells, providing help to B cells 
and CD8 T cells, and as effectors. For example, IL-2 from CD4 T cells helps tune NK cell 
proliferation, IFNγ secretion and recognition of MHC class I-devoid cells (reviewed in 174). 
On the other hand, licensed NK cells activate and augment CD4 T cell differentiation, 
proliferation and function through production of proinflammatory cytokines 175 and co-
stimulation 176 but can also kill infected and stressed T cells when they upregulate death 
receptors or ligands for NK cell activating receptors (reviewed in 177). 
 
Tregs are specialized CD4 T cells that counteract inflammatory processes to dampen immune 
responses and thus protect the host from immune-mediated pathology, although this 
sometimes leads to the persistence of pathogens (reviewed in 178, 179). Tregs also protect 
against autoimmunity as many of them express TCRs with high affinity for self-antigen. As 
such Tregs can be found in various tissues, both lymphoid and non-lymphoid, and 
particularly in sites of inflammation. There are two major subsets of Tregs: those that exit the 
thymus as Tregs (or natural Tregs; nTregs) and those that differentiate from CD4 T cells in 
the periphery in the presence of appropriate cytokines and antigen (peripheral/induced Tregs; 
pTregs/iTregs). Central Tregs (cTregs) circulate between blood and secondary lymphoid 
tissue where they actively block the priming of naïve CD4 T cells if self-antigen is present 
through the ligation of inhibitory receptors on dendritic cells. Homeostatic maintenance of 
Tregs is IL-2- and FOXP3-dependent, thus they highly express the high affinity IL-2 receptor 
α CD25 while only low amounts of the IL-7 receptor CD127 180. Once activated, cTregs 
differentiate into effector Tregs (eTregs) that are resident in non-lymphoid tissue and can be 
recruited to sites of inflammation where they act to counter inflammatory processes through 
production of cytokines like IL-10, activation of apoptosis, or interruption of metabolic 
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pathways. They express multiple homing and adhesion receptors/ligands that facilitate their 
entry into the periphery, and are maintained through IL-33, in addition to TCR and 
costimulatory molecule signals. It should be noted that proinflammatory cytokines such as 
IL-1 and type-1 IFN impede Treg function. On the other hand, Tregs can dampen NK cell 
function (reviewed in 174) and T cell expansion 181 by limiting the IL-2 available to them. 
 
T-bet and Eomes are the transcription factors governing the differentiation of naïve CD8 T 
cells to effector cells. Akin to NK cells, CD8 T cells are primarily cytotoxic, killing virus-
infected, malignant, and stressed cells through perforin and granzyme B (GrzB), but also 
produce cytokines. They require CD4 T cell help to function optimally (reviewed in 171, 182) 
Through the binding of CD40L on CD4 T cells to CD40 on DC, they license the DC to 
efficiently prime CD8 T cells to perform cytotoxic function 183. Antigen-stimulated naïve 
CD8 T cells that do not receive CD4 T cell help undergo activation-induced cell death 
when they encounter secondary stimulation. However, IL-15 expressed by licensed DCs 
can be sufficient to activate CD8 cytotoxic responses without CD4 T cell help. The 
cytokines IL-2 and IL-12 are necessary for antigen-specific CD8 T cell responses 184 as 
they stimulate clonal expansion and improved function. The need for IL-2 is tied to its 
effect on CD8 T cell metabolism and transcription through mTORC1, which affects 
differentiation into effector cells 185. IFNγ from CD4 T cells directs the recruitment and 
maintenance of tissue-resident memory CD8 T cells in a chemokine-dependent manner in 
response to mucosal infection. In addition, CD4 T cell derived IL-21 is necessary for the 
maintenance of effector CD8 T cell clones and activity in chronic viral infections, while IL-
10 from regulatory T cells dampens the pro-inflammatory response and thus allows CD8 T 
cell memory maturation while protecting from exhaustion. CD4 T cells can also directly co-
stimulate CD8 T cells through CD40 ligand – CD40 interactions, thus obviating the need 
for APC 186. Furthermore, direct T cell-to-T cell interactions during the priming phase in 
the lymph node contribute to the differentiation and generation of protective memory CD8 
T cells 187. Thus dysregulation of CD4 T cell frequency, phenotype and function affects the 
quality of CD8 T cell function. 
 
Activated T cells up-regulate a number of surface molecules including CD38 and HLA-DR, 
to mention but a few. CD38 is a transmembrane glycoprotein whose upregulation early 
during T-cell activation leads to changes in cell metabolism 188, cell-to-cell adhesion and 
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movement through the endothelial cell wall 189 and cytokine production 190 (reviewed in 191). 
HLA-DR is an MHC class II receptor that is involved in antigen presentation, but that is also 
upregulated in response to activation 192, 193. As earlier mentioned T cells require a co-
stimulatory signal, in addition to the CD3-TCR-CD4/8 complex and cytokine signals. Some 
co-stimulatory receptors can deliver either activating or inhibitory signals depending on 
which ligand they bind (reviewed in 194). For example, either of the ligands CD80 and CD86 
on APCs can bind either of receptors CD28 or cytotoxic T lymphocyte antigen 4 (CTLA-4) 
on T cells, resulting in either an activation or inhibition signal respectively. Inhibition signals 
are utilized to modulate the activation signal, thus avoiding hyper activation whilst tuning cell 
differentiation and maturation. Another negative regulator of function is programmed death-1 
(PD-1) and its ligand PDL-1. It should be noted that in the case of persistent immune 
activation, such as happens with chronic viral infections, T cells up-regulate a number of 
these negative regulators of function in a bid to counteract chronic stimulation 195: this up-
regulation is associated with a state of exhaustion (that is, dysfunction seen in impaired 
proliferative ability and effector function) 196.  
 
2.4 Unconventional T cells 
The description of the human immune system as bimodal is in a number of ways an 
oversimplification, as the discovery of cell types displaying a hybrid innate-adaptive 
character has increased (reviewed in 197). In general these cells express surface receptors of 
restricted antigen specificity and constitutively display adaptive-like characteristics (for 
example memory), although highly specific cells displaying innate-like function (for 
example responding rapidly) have also been described (reviewed in 198, 199). Unconventional 
T cells include T cells displaying αβ TCRs that are semi-invariant and not MHC-restricted. 
Mucosal associated invariant T (MAIT) cells are a large innate-like T cell subset constituting 
up to 10% of T cells in peripheral blood, but are also found in liver and mucosal sites, and 
throughout the body. The semi-invariant TCR consists of a Vα7.2-Jα33 chain bound to an 
oligoclonal CDR3β-chain, which recognizes antigens presented on MR1 (reviewed in 200). 
MR1-presented antigens are intermediates of the riboflavin biosynthesis pathway, thus these 
cells are important in fighting bacterial and some fungal infections. They can also be 
activated by cytokines such as IL-12 and IL-18 resulting in the production of IFNγ.  
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Invariant natural killer T (iNKT) cells are innate-like T cells whose invariant TCR recognizes 
lipid and glycolipid antigens (reviewed in 201) presented by the non-classical CD1d molecule 
(reviewed in 202). They constitute only up to 1% of peripheral blood T cells although they are 
found more abundantly in tissue. Three subsets of iNKT cells have been described, namely 
type I, type II and type Ia NKT based on the composition of the TCR and antigens they 
recognize (reviewed in 203); this thesis shall focus on type I, hereafter referred to as iNKT 
cells. The lipid α-galactosylceramide is the archetypical antigen for the iNKT cell TCR that is 
composed of a Vα24 and Jα18-containing α-chain bound to Vβ11-containing β-chain. Both 
self and foreign lipid antigens (particularly from bacteria) are recognized for thymic selection 
and tuning, and immune activation respectively. They constitutively express a number of 
activating NK receptors in addition to cytokine and chemokine receptors (such as CCR5 and 
CXCR4) that help them home to inflamed tissues, where they are found more abundantly. 
Like conventional T cells, they require IL-15 for maintenance and express either CD4, CD8 
or none of them (double negative), although the majority express CD161 (reviewed in 204). 
Conversely, iNKT cells can be activated by either a TCR, cytokine (such as IL-12 and IL-18) 
or activating receptor signal 205. Activation results in rapid production of large amounts of 
both proinflammatory and immunoregulatory cytokines and chemokines (IFNγ, IL-4, IL-17, 
CCL3, CCL4, CCL5) and cytolysis (granzyme B and Fas-mediated apoptosis); thus iNKT 
cells are important in directing innate and adaptive immune responses to both PAMPs and 
DAMPs in a bidirectional manner (reviewed in 202 206). 
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3 HIV AND THE IMMUNE SYSTEM 
3.1 Overview 
The study of the interaction of HIV with the human immune system has dramatically 
accelerated our understanding of host-pathogen interactions. While there is a major 
immune bottleneck at the point of transmission 42, once HIV infection occurs, it 
utilizes the immune system to cause an infection, rapidly replicate and establish latent 
viral reservoirs. This results in persistent inflammation and loss of CD4 T cells that 
leads to chronic activation, and eventual disease and death particularly in the absence 
of control of viraemia (Figure 3). Interestingly, even when viral replication is 
controlled to levels below detection by conventional tests, there is still residual 
replication that is suspected to cause the residual inflammation and activation that has 
been associated with non-AIDS morbidity. The following section delineates the 
contribution of different cell types to the immune control of HIV.  
 
Figure 3. A simplified timeline of untreated HIV infection. 
 
3.2 NK cells 
At mucosal sites HIV-1 is recognized by epithelial cell TLRs triggering the release of 
cytokines such as IFNα and chemokines such as MIP-1α that attract and activate APCs 
124, 207. DCs process and present antigen, and release cytokines such as IL-12 and IL-18 
that activate innate immune cells including NK cells and other effector populations that 
mediate antiviral activity (reviewed in 208). 
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HIV-1 accessory proteins Nef and Vpu inhibit antigen presentation in infected cells by 
downregulation of surface MHC class I molecules. This allows the virus to evade 
detection and cytolysis of the infected cell by CD8 T cells, while modulating NK cell 
recognition of infected cells 209. This can lead to NK cell production of IFNγ 141, TNF 
210, β-chemokines and cytotoxic killing of autologous 211 and allogeneic 212 HIV-
infected CD4 T cells through direct recognition and cytolysis or ADCC (reviewed in 
213). The NK cell repertoire changes in response to HIV-1 infection, suggesting these 
cells become engaged in a systemic manner in fighting the virus 214-217 (reviewed in 
124). NK cells have been suggested to protect highly exposed seronegative injecting 
drug users 218 and women at high risk of HIV infection from acquiring the infection 219, 
220. Certain KIR-HLA genotypes are associated with protection from HIV acquisition, 
low viraemia and slow progression to AIDS (reviewed in 221). Conversely, poor 
function in activated NK cells pre-infection 222 and certain KIR-HLA combinations 223 
may be associated with higher risk of HIV acquisition. In rhesus macaques, SIV-
specific CD4 T cells activate NK cells in an IL-2 dependent manner leading to better 
control of infection 224. HIV vaccine induced NK cell ADCC has been associated with 
reduced HIV infection risk in the RV144 trial 225, 226, while high levels of passively 
acquired HIV-specific antibodies in infants were associated with reduced mortality risk 
227.  
 
HIV-1 uses many strategies to escape NK cell activity (reviewed in 228-230): Some HIV 
peptides can alter the binding ability of inhibitory KIRs to their HLA ligands towards 
greater NK cell inhibition 231. Infection is associated with altered expression of 
inhibitory and activating receptors 145, 232-236 (reviewed in 124) geared towards impairing 
cytolytic activity, and compromised ability to kill immature DCs and thus direct 
adaptive immune responses 237 (reviewed in 238). NK cells display impaired secretion 
of cytokines and chemokines 239, impaired ADCC 240, 241 and respond poorly to 
cytokine activation 242. In chronic infection a dysregulated CD56neg NK cell subset 
expands 144 (reviewed in 243). In vitro experiments also show impaired recruitment and 
activation of NK cells by dendritic cells exposed to complement-opsonized HIV 244. 
Conversely, HIV utilizes NK cells to compromise the immune response by, for 
example, killing of CD4 T cells through NKp44-NKp44L 61. 
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3.3 Conventional adaptive T cell responses 
While it is not yet clear what role immune activation levels play in HIV acquisition 222, 
245, 246, the chronic immune activation that occurs subsequent to infection, particularly 
in T cells, is a hallmark of HIV infection and predicts morbidity and mortality 247, 248 
(reviewed in 249). As mentioned previously, HIV mainly infects CD4 T cells, directly 
and indirectly leading to their death, and thus compromises host immune responses. 
The HIV envelope protein gp120 binds both the CD4 receptor and either of the 
chemokine receptors CCR5 250 and CXCR4 251 to facilitate its entry into a target cell 
(reviewed in 49, 65). The gut contains a large proportion of HIV susceptible CD4 T cells 
and the intense viral replication depletes CD4 T cells and compromises the gut barrier 
already in acute infection, leading to increased translocation of microbial products into 
the tissues and circulation (reviewed in 252). Gut damage is associated with alterations 
in the microbiome, both local and systemic inflammation that in turn activates immune 
cells, and recruitment of immune cells (through CCR5) 253 thus increasing the pool of 
HIV targets. This, together with bystander activation 254 is a major contributor to 
chronic immune activation 67. The importance of CD4 T cells in the immune response 
to HIV infection is underscored by the discovery that polyfunctional CD4 T cell 
responses were a correlate of protection against HIV acquisition in the RV144 trial 255.  
 
CD4 T cell loss is associated with a marked increase in activated HIV-specific CD8 T 
cells that are poor at inhibiting HIV replication and predictive of disease progression 
256. This may be due to selection of escape variants of virus 257, 258 and results in an 
‘arms-race’ between CD8 T cells and the virus 259, 260 (reviewed in 261). Non-specific 
CD8 T cells also markedly expand: later on there is increased bystander activation 262 
and cycling of memory CD8 T cells that is associated with distortion of the structure of 
lymph nodes due to fibrosis 68. Furthermore, polyfunctional CD8 T cells are believed 
to be important for control of viral replication in acute HIV infection and for long-term 
non-progressive disease that occur in rare patients 263-265. Such efficient CD8 T cell 
responses also occur in elite controllers 266, 267 (more resistant to apoptosis 268), and also 
display a memory response to viral rebound of SIV in pig-tailed macaques 269. 
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Conversely, the HIV protein Tat activates CD8 T cells and may contribute to 
hyperactivation and exhaustion 270. 
 
3.4 Invariant NKT cells and Tregs 
Similarly, HIV can infect nTregs 271, 272 (reviewed in 273) and iNKT cells 204 that 
express both CD4 and either of CCR5 or CXCR4 leading to their depletion. 
Interestingly, the transcription factor FOXP3 found in nTregs has been reported to 
have anti-HIV properties, which, in addition to resistance to apoptosis and altered 
expression of CD25, may partly explain the disparate results of Treg frequency, 
number and function in HIV infection 274-276 (reviewed in 179, 273). However, although 
they play a protective role in highly exposed seronegative individuals, Treg 
preservation does not lead to better control of chronic immune activation 277 (reviewed 
in 179). On the other hand, iNKT cell depletion is associated with increased immune 
activation in SIV-infected macaques 278. In HIV the remaining iNKT cells express less 
cytokine and proliferate poorly to both cytokine and TCR stimulation in in vitro 
experiments. HIV proteins Nef and Vpu modulate activation of iNKT cells by 
inhibiting CD1d cell surface expression and antigen presentation 279-281, suggesting that 
iNKT cells do play a role in HIV immune control. Interestingly, recent findings 
indicate that iNKT cells can detect HIV infection if Nef and Vpu activity is abolished 
282. 
 
3.5 Role of chronic immune activation 
Persistent immune activation and inflammation is a hallmark of untreated HIV 
infection (reviewed in 283). Signs of chronic activation of immune cells in infected 
persons include elevated expression of activation markers such as CD38 and HLA-DR 
284-286, and inhibitory receptors such as PD-1 196, 287, 288 and TIM-3 277, 289(reviewed in 
290, 291). Persistent activation is also accompanied by altered expression of cytokine and 
chemokine receptors 292, altered production of cytokines 293 and chemokines plus 
aberrant killing ability 294, increased apoptosis 295, 296, skewing of populations of cell 
subsets 297, 298, impaired immune regulation 277, and immunosenescence (reviewed in 
299, 300). All these events and factors exhaust the immune response and predispose the 
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HIV-infected individual to opportunistic infections and cancers that are the typical 
causes of death. On the other hand, while ART preserves immune cell phenotype and 
function, gut integrity and lymph node structure, the residual low-level viral replication 
leads to residual immune activation that is suspected to be the cause of increased non-
AIDS defining illnesses and accelerated aging. It is clear that it is important to prevent 
the establishment of a hyper activation state that begins within days of infection 59 as 
natural SIV hosts (Sooty mangabeys and African green monkeys) arrest immune 
activation early and thus do not develop AIDS despite continuous viral replication 
(reviewed in 69, 249). Innate immune mechanisms, as the earliest responses to HIV 
infection may be the key to this. Pig-tailed macaques infected with a replication- and 
disease- competent mutant of SIVmac239 also control virus and maintain health 
through both innate and adaptive mechanisms 269. This thesis thus aimed to 
characterize innate cellular immunity in the immunopathogenesis of HIV infection in 
Uganda, in a bid to inform the development of better vaccines or therapies for HIV. 
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4. AIMS 
HIV-1 infection continues to be a major cause of morbidity and mortality in sub-
Saharan Africa. In Uganda, HIV-1 subtype A infection is associated with 
significantly slower progression to AIDS than subtype D infection. The main 
objective of this thesis was to significantly enhance our understanding of the role of 
innate cellular immunity in HIV-1 infection, and contribute to the body of knowledge 
leading to better vaccines and therapeutics. Thus the specific aims of this thesis were 
as follows: 
 
Specific Aim 1: Establish normal reference ranges for lymphocyte subsets in 
Ugandans, including NK cells. Thus far, no study with a sufficiently large sample size 
and good representation of urban and rural Ugandan populations had been done. 
Country-specific reference values are very important for the design and interpretation 
of both basic studies and intervention trials where immunological parameters are of 
importance. (Paper I) 
 
Specific Aim 2: Investigate the differential loss of regulatory subsets of T cells in 
HIV-1 subtype A and D infection. iNKT cells are innate-like T cells that direct innate 
and adaptive cell responses to an infection through their production of 
immunoregulatory and activating cytokines. Tregs modulate immune responses to 
infection to avoid immune activation-mediated pathology. We thus aimed to 
investigate if distribution of these cell subsets associated with the differential 
immunopathogenesis of subtype A and D infection. (Paper II) 
 
Specific Aim 3: Determine the basis for the functional impairment of NK cells to 
cytokine stimulation in HIV-1 infected subjects. IL-12 and IL-18 are major cytokines 
involved in NK cell activation during an infection. The IFNγ NK cells release after 
cytokine stimulation is important not only for the anti-viral activity of this cytokine, 
but also the immunomodulatory effects on dendritic cell maturation that influence 
antigen presentation and T cell priming. (Paper III) 
 
Specific Aim 4: Investigate the role of FcγRIIIA+ CD8 T cells in HIV-1 infection. 
CD16 is commonly expressed on innate immune cells like NK cells, monocytes and 
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neutrophils, and is involved in antibody-dependent cell-mediated cytotoxicity or 
phagocytosis. We sought to characterize the levels, characteristics and function of 
FcγRIIIA+ TCRαβ+ CD8 T cells and investigate their role in HIV-1 infection. (Paper 
IV) 
 
Specific Aim 5: Assess the contribution of markers of inflammation to immune 
activation. Recent data shows that, unlike what is seen in western cohorts, viral load, 
but not T cell activation levels, was an independent predictor of disease progression in 
rural Ugandans. We sought to characterize innate soluble markers of inflammation and 
immune activation and identify predictors of HIV disease progression in this 
population. (Paper V) 
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5. METHODS 
5.1 Flow Cytometry 
Whole blood collected from participants in a long-term community-based cohort of 
HIV surveillance 301 was processed and PBMCs cryopreserved according to 
previously established procedure 302. On the day of experimentation cryopreserved 
specimens were thawed and washed. Counts and viability were assessed on the 
Guava PCA (Guava Technologies, Hayward, CA, USA), using Guava ViaCount 
reagent. Standard flow cytometry phenotyping was performed as previously 
described 145. For assessment of transcription factors, cells were washed, 
permeabilized and fixed using an optimized kit (FoxP3 staining fix/perm, 
Ebiosciences) before intranuclear staining. Flow cytometry data were acquired with a 
BD LSR II instrument or a BD FACS Canto II instrument (BD Biosciences). Sorting 
was performed on a 4-laser special order BD FACS ARIA II SORP (BD 
Biosciences) contained in a biosafety cabinet. Clinical lymphocyte 
immunophenotyping was performed using the FACS MultiSET System and run on a 
FACSCalibur using the single platform Multi-test 4-color reagent in combination 
with TruCount tubes (BD Biosciences). The different panels studied are detailed in 
Table 1 and 2 below, although actual clone and manufacturer details can be found in 
the different papers. 
 
Table 1: Flow panels used in thesis research 
 
 
 
Laser Fluorochrome NK phenotype NK function NK function iNKT T cell function Treg T cell activation
FI TC/ AL488 CD57 CD57 CD57 Vα24 I L-2 FoxP3 HLA-DR
PE Ki67 Perforin I FNγ Vβ11 TNFα CD25 PD-1
PerCP-
Cy5.5/ PE-Cy5 CD3 CD3 CD3 CD3
PE-Cy7 CD56 CD56 CD56 CD8 CD8
Pac Blue/ V450/ B HLA-DR HLA-DR HLA-DR CD4 CD4 CD4 CD4
AmCyan/ V500
Aqua Live/ Dead Live/ Dead Live/ Dead Live/ Dead Live/ Dead Live/ Dead Live/ Dead
BV785
APC/ AL647 NKG2A NKG2A NKG2A CD161 I FNγ CD127 CD38
APC-Cy7/ APC-
H7
CD3/ CD14/ CD
19
CD3/ CD14/ CD
19
CD3/ CD14/ CD
19
Alexa700 
PE
PE-CF594
PE-Cy5
PE-Cy7
I I I I I I I I I I I I I I I V
BD Facs Canto I ICytometer used
Blue 
488nm
Violet 
405nm
Red 
640nm
Green 
532nm
Papers used in:
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Table 2: Flow panels used in thesis research 
 
 
5.2 Soluble factor analysis  
Soluble factors were measured either by a human inflammatory cytokine bead array, 
custom multiplex cytokine array or by enzyme-linked immunosorbent assays 
(ELISA) commercial kits as per manufacturer’s instructions. Optical density 
(ELISA) was determined using a BioTek ElX800 plate reader and final 
concentrations were calculated from standard curves using KC4 software (BioTek, 
Winooski, VT). All samples were run in triplicate and mean values were used for 
data analysis. Details of soluble factors studied can be found in the different papers. 
 
5.3 Gene expression analysis  
Stained cells were sorted into wells (~1000 cells/well) containing 10 μl of reaction 
buffer (SuperScript III Reverse Transcriptase / Platinum Taq Mix, Cells Direct 2X 
Reaction Mix, Invitrogen). Reverse transcription and specific transcript amplification 
were performed using a thermocycler (Applied Biosystems Gene Amp PCR System 
9700) as follows: 50°C for 15 min, 95°C for 2 min, then 95°C for 15 sec, 60°C for 30 
sec for 18 cycles. The amplified cDNA was loaded into Biomark 96.96 Dynamic 
Array chips using the Nanoflex IFC controller (Fluidigm). This microfluidic platform 
was then used to conduct qPCR in nl reaction volumes. Threshold cycle (CT), as a 
measurement of relative fluorescence intensity, was extracted from the BioMark 
Real-Time PCR Analysis software. Amplified genes were qualified according to 
Laser Fluorochrome
T cell 
activation
T cell 
differentiati
on I
T cell NK 
receptors T cell homing
T cell
differentiati
on I I
T cell
transcription 
factors
T cell 
phenotype
T cell
phenotype 
(Fluidigm)
T cell 
phenotype 
(ADCC) T cell function
FI TC/ AL488 TCRab CCR7 CD57 CXCR3 Perforin Tbet CD107a
PE PD-1 TRAI L NKp46 Eomes
PerCP-
Cy5.5/ PE-
Cy5 CD3 CD27 NKG2D CD16 CD161 CD8 KI R2DL1/ S1
PE-Cy7 CD8 CD8 CD8 CD8 CD8 CD56
Pac 
Blue/ V450/ B
V421/ eFlour
450 CD16 CD16 CD16 CCR5 CD16 Helios CD16 CD16 CD16
AmCyan/ V50
0 CD3
Aqua Live/ Dead Live/ Dead Live/ Dead Live/ Dead Live/ Dead Live/ Dead Live/ Dead Live/ Dead
BV785 CD45RA CD45RA CD45RA CD45RA
APC/ AL647 CD38 CD45RA NKG2A PD-1 I L-7R CD57 CD57 CD57 CD57
APC-Cy7/ APC-
H7 CD3 CD3 CD3 CD3 CD16 CD8 CD8 CD8 CD8
Alexa700 KI R3DL1 
PE
KI R2DL2/ DS
2/ DL3 I FNγ
PE-CF594 CD3 CD3 CD3 CD3
PE-Cy5 CD14/ CD19 CD14/ CD19 CD14/ CD19
PE-Cy7 CD56 CD56 CD56 CD56
I V I V I V I V I V I V I V I V I V I V
Green 
532nm
Papers used in:
Cytometer used BD LSR I I
Blue 
488nm
Violet 
405nm
Red 
640nm
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whether they were efficiently amplified; the amplification was linear and was not 
affected by multiplexing 303. Subsequent data analysis was performed using JMP 
software (version 10). Details of genes studied can be found in Paper IV. 
 
5.4 ADCC assays  
Measurement of ADCC was performed using the PanToxiLux (PTL) assay 
(OncoImmunin, Inc., Gaithersburg, MD, USA). Recombinant HIV-1 BaL gp120 
from DAIDS, NIAID catalog #4961 and HIV-1 rgp 120 IIIB (CHO), catalog #1174 
(obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH) 
were used to coat targets CEM.NKRCCR5 cells. Optimum concentration used to coat 
target cells was determined for each gp120 through an 11-point titration starting with 
20 μg/ml and serial diluting 2-fold. After coating target cells were labeled with TFL4 
(OncoImmunin, Inc.), a fluorescent target-cell marker, washed and stained with 
viability dye LIVE/DEAD Fixable Aqua Dead Cell Stain (Life Technologies). Target 
cells were then resuspended together with sorted effector cell populations for an 
effector to target ratio of 30:1, in the presence of GrzB substrate (OncoImmunin, 
Inc.). After incubation Human Immunodeficiency Virus Immune Globulin (HIV-
IG™) (North American Biologicals, Inc., Miami, FL, USA) was added to each well, 
and the plate incubated then washed. Cells were acquired on the LSRII (BD 
Bioscience) the same day. Fluorophores were detected using: a 488 nm 50 mW laser 
with 515/20 filters to detect GrzB substrate, a 406 nm 100 mW laser with 525/50 
filters to detect Aqua L/D stain, and 640 nm 40 mW laser with 670/30 filters to 
detect TFL4 stain. Data were analyzed by using FlowJo 9.7.5 (Ashland, OR, USA). 
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6. RESULTS AND DISCUSSION 
6.1 Lymphocyte subset distributions in Ugandan populations  
The human immune system is composed of a complex network of cells that work in 
concert to protect the host from pathogen attack while avoiding immune-mediated 
pathology. It includes antigen-presenting cells such as dendritic cells and 
macrophages, granulocytes such as neutrophils, eosinophils and basophils, and 
lymphocytes such as T, B and NK cells. Hematology and clinical immunophenotyping 
are basic laboratory tests utilized routinely to guide clinical management of patients, 
with the latter being especially important in the case of HIV infection. In the context 
of research, baseline data on these parameters can help formulate research hypotheses, 
and is used to identify and characterize clinically relevant abnormalities. In addition, 
such data can be important in guiding choice of potential participants for clinical trials. 
In Paper I we sought to establish normal lymphocyte reference ranges for Ugandans 
using blood collected from healthy blood bank donors. We found substantial sex-
associated differences between women and men, with women having higher 
frequencies and counts for all lymphocytes with the exception of the frequencies of 
CD8 T cells and B cells that were similar, and frequencies and counts of NK cells that 
were higher in men (Paper I, Table 2). Of note, basophil counts positively associated 
with overall T cell counts. 
 
Previous studies have shown that immune responses to viral infections differ between 
the sexes 304-307 (reviewed in 308). In the context of HIV immunopathogenesis sex 
differences have been noted, with women displaying better clinical and virological 
outcomes in some data 309-311, and worse in others 312-314. Immune activation and 
inflammation both at the protein 315 and soluble biomarker level 316 also showed sex 
differences, with the latter study showing less reduction in inflammation and activation 
in the first year of ART for women, but with the former showing the reverse after years 
of ART. All this suggests that the sex differences probably i) stem from genetic and 
hormonal differences (reviewed in 317) ii) are revealed by data such as that presented in 
Paper I, and iii) have implications for disease outcomes. For example, a study by 
Weinberg et al revealed an increase of peripheral Tregs that suppressed immune 
responses in association with increases in progesterone 318. Sex differences also 
manifest in the pharmacokinetics and pharmacodynamics of drugs, including ART, so 
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much so that some drug regimens are prescribed differentially 319.  
 
Although we show that basophil counts positively associated with T cell counts in both 
sexes, the association was stronger in women (Paper I, Fig. 3 and 4). Thus basophils 
may probably more strongly modulate immune responses 320 and be one of the 
contributors to greater immune activation and inflammation seen in women (reviewed 
in 321), particularly those with a significant parasitic burden (reviewed in 322, 323). 
Recent research also shows sex differences in metabolism 324; as nutrition influences 
metabolism, and metabolism influences immune responses 151, 185, this may contribute 
to the cellular differences seen here, and to differential HIV immunopathogenesis. 
Furthermore, studies have shown sex differences in cellular function and phenotype 325, 
326.  
 
Interestingly, when we compared participants of two different cohorts, one urban and 
the other rural, to the semi urban blood bank donors, we found significant differences 
in both lymphocyte and hematological parameters, particularly in males. The three 
cohorts were disparate in terms of urbanicity but similar as regards heterogeneity of 
tribes (thus genetics) and altitude. Differences in cell subset proliferation and numbers 
have previously been recorded between ethnic groups in the same environment 327, 328 
in the context of HIV infection, within an ethnic group dispersed in different countries 
329 and within different locations in the same country 330. We hypothesize that 
nutrition, socio-economic status and composition of the intestinal microflora may 
contribute to the differences seen between these groups, although it is possible that 
subclinical conditions not evaluated while taking medical history could influence the 
results 331, 332. These results are relevant to HIV immunopathogenesis: a study 
conducted in semi urban districts of Uganda showed that antiretroviral therapy–naive 
HIV-positive adults with poor diet quality were more likely to be less educated and 
more socio-economically disadvantaged, and poor diet quality was positively 
associated with anemia and low CD4 counts in addition to predicting mortality 333. 
Another study conducted to investigate prevalence of intestinal parasites in two sub-
ethnic groups living in the same area in Malaysia found that the statistically significant 
differential parasitic burden was influenced by socioeconomic factors 334. It is thus of 
interest that males revealed more location differences than women, as it points toward 
socioeconomic factors. Additionally, it emphasizes the need to not only include but 
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also endeavor to balance different demographic groups during data collection and 
analyses so as to pick up any important differences (reviewed in 335, 336) or at the very 
least validate the reference ranges using a sample of the population of interest 337. Thus 
further research with sufficient statistical power to detect how demographic differences 
may impact future clinical studies and trials are needed 312, 338 (reviewed in 321). 
 
6.2 Natural killer cell phenotype and function in HIV-1 subtype D infection 
HIV-1 subtype D infection is characterized by faster disease progression than subtype 
A infection in Ugandans, for yet to be defined reasons. Natural killer cells are 
important effectors of viral control in virus infections that direct both innate and 
adaptive immune responses. They are innately primed to respond to cells expressing 
stress ligands and/or missing MHC class I receptors. In order to function optimally, 
NK cells utilize a plethora of activating and inhibitory receptors that tune the threshold 
of activation thus protecting self against NK-mediated pathology. In HIV, they have 
been shown to help protect against acquisition, inhibit viral replication, and influence 
disease progression. In Paper III we investigated if NK cell phenotype and function 
influenced immunopathogenesis of subtype D infection in chronic untreated HIV-1 
infected Ugandans.  
 
In this cross sectional study, we found that CD56dim NK cells from HIV-infected 
persons produced less IFNγ compared to uninfected controls, when stimulated with the 
cytokines IL-12 and IL-18 (Paper III, Fig. 1b and Fig. 1c). This was in contrast to 
stimulation with MHC-null K562 cell line, which showed no difference. Surprisingly 
there was no difference in either cytolytic (perforin) or proliferation ability (Ki67) of 
the CD56dim NK cells seen as measured ex vivo, regardless of infection status. HIV-
infected individuals had a lower representation of NKG2A+CD57+ CD56dim NK cells 
than the healthy controls (Paper III, Fig. 1f and Fig. 1g); this subset was highly 
activated (HLA-DR; Paper III, Fig. 1h) and its frequency correlated directly with 
CD56dim NK cell IFNγ production in response to IL-12 and IL-18 stimulation (Paper 
III, Fig. 1i), but not K562 stimulation (Paper III, Fig. 1j). Of note, these changes in 
CD56dim NK cell phenotype and function were independent of CD4 T cell count and 
viral load. We concluded that these changes reflected an HIV-driven change in NK 
cell maturation that was accompanied by activation and poorer response to cytokine 
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stimulation.  
 
IL-12 and IL-18 are innate cytokines that activate immune cells differentially to 
respond to pathogens. IL-12 stimulates NK cell production of IFNγ that skews naïve 
CD4 T cell differentiation to Th1 necessary for antiviral and antibacterial activity 
(reviewed in 171, 339), and enhances NK cell - CD4 T cell crosstalk 141, 175, 176 hence 
influencing adaptive immune responses. Cytokine stimulation also enhances NK cell 
cytotoxicity, both through perforin and Fas-Fas ligand pathways 340-342. Thus the 
defect in NK cell IFNγ production could lead to poorer immune responses to not only 
HIV but also opportunistic infections. 
 
NK cells show defects in function in chronic infection, regardless of ART status 342. 
HIV-infection impairs the anti-fungal ability of NK cells by compromising NKp30 
expression and impairing the perforin pathway 342. Stimulating the NK cells in vitro 
with recombinant human IL-12 restored NK cell function measured by perforin 
expression. However, this study did not assess the ability of these NK cells to 
produce IFNγ, despite there being conflicting results on whether the cytokine is 
important for anti-fungal activity 128, 343 (reviewed in 344). Thus, it is possible that Kyei 
et al would have found a defect in NK cell IFNγ production, and that we would have 
found a defect in NK cell perforin expression had we stimulated the NK cells ex vivo. 
Taken together it appears that NK cells display multiple defects in HIV infection that 
are only partially rescued by exogenous cytokine. This data is important particularly 
for the incidence and reactivation of fungal infections in the HIV-infected population 
in Uganda, as fungal diseases are quite common 345. Significantly immunosuppressed 
persons starting ART are at high risk for developing immune reconstitution 
inflammatory syndrome (IRIS), a condition in which patients deteriorate paradoxically 
despite both mycologic and virologic suppression 346. Meya et al showed an increase 
of activated CD56dim NK cells, CD4 T cells and proinflammatory monocytes in the 
cerebrospinal fluid of HIV-infected persons displaying cryptoccocal meningitis-IRIS 
347. It is worth noting that patients who display high Th2 and Th17 responses but low 
proinflammatory cytokines pre-ART are predisposed to develop IRIS post-ART 348. 
Inflammasome activation leads to excessive inflammatory monocyte responses and 
ineffective T cells associated with mycobacterium tuberculosis-IRIS in HIV-TB 
coinfected persons 349. All these, together with the pathogen-associated skewing of NK 
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cell phenotype subsets described here and elsewhere 125, 233, 350, 351 reveal the 
importance of NK cells to the immune response.  
 
In HIV infection, persistent inflammation and immune activation begins early in 
infection and is not resolved even when ART is started in acute infection 59, 352. This 
suggests other drivers of inflammation and activation or low-level viral replication in 
local sites 352, 353. Thus the defects we see here could have begun early in infection. 
Although the prevalence of hepatitis B, hepatitis C and syphilis were low, we did not 
evaluate these participants for other coinfections that may contribute to the immune 
dysregulation we see here. Nevertheless, the data presented has implications for the 
immune response to incident infections during HIV-1 infection 354 and thus 
cumulatively lead to more rapid progression of HIV-1 subtype D infection. 
 
6.3 Differential associations of interleukin 6 and intestinal fatty acid-binding 
protein  
High levels of inflammation and immune activation begin in acute HIV infection and 
persist through chronic infection and are associated with morbidity and mortality in 
treated and untreated infection. In this study, we examined indices of immune 
activation and inflammation in Ugandans with chronic untreated HIV-1 infection. 
We found that IL-6, soluble CD14 (sCD14), soluble CD163 (sCD163), and catalase 
were elevated in HIV-1– infected study participants compared with uninfected 
individuals, although C-reactive protein (CRP), intestinal fatty acid binding protein 
(IFABP), IL-10, and neopterin did not differ significantly (Paper V, Table 1). A 
trend toward lower levels of IFABP was observed in HIV-positive participants 
compared with HIV-uninfected individuals (Paper V, Table 1). Viral load, T-cell 
activation and IL-6 levels associated with faster disease progression (Paper V, Fig. 
1A) and with each other (Paper V, Fig. 1B). Surprisingly, even though IL-6 levels 
associated with CRP levels, IFABP levels associated neither with viral load nor with 
sCD14 (Paper V, Fig. 1B). 
 
Our data on soluble biomarkers of inflammation from this rural African population 
differed from what has been described extensively in the literature, where neopterin 
and CRP predict HIV disease progression 355 (reviewed in 356-358). In addition, 
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contrary to what is described in the literature (reviewed in 359), IFABP was lower in 
HIV-infected participants compared to uninfected ones. Sub-Saharan Africa is 
endemic for many infections, particularly enteric ones 360, which may stimulate an 
inflammatory state independent of HIV-1 infection, so that HIV-infection does not 
dysregulate the gut above the other infections. Furthermore, accelerated enterocyte 
turnover facilitates expulsion of gut parasites 361 that are endemic to sub-Saharan 
Africa (reviewed in 362); suggesting that lower IFABP levels in fast progressors 
compared to slow progressors may be a mark of dysregulated immune responses. 
Although sCD14 and IFABP have been used interchangeably as markers of 
microbial translocation, they were inversely correlated in our data, which is more in 
line with IFABP being a marker of slower progression in our cohort. This could also 
be reflective of independent biological processes in this cohort. Taken together, our 
data reveals differences in known soluble biomarkers of inflammation between 
cohorts from different regions that warrant more detailed investigation 363.  
 
Consistent with other studies (reviewed in 356), markers of monocyte activation and 
inflammation were all increased in HIV-positive individuals compared with negative 
participants. In spite of this, CRP levels did not associate with viral load, suggesting 
multiple independent drivers of inflammation in this cohort. Again, the prevalence of 
Hepatitis B and C and active syphilis were low and did not differ between 
progression groups and uninfected, however, we did not test for other coinfections 
that could possibly contribute to the results described here (reviewed in 364). In the 
era of ART it is important to delineate which pathways contribute strongest to both 
AIDS and non-AIDS comorbidities (reviewed by 356), as this will guide future 
therapeutics and vaccines. A recent study conducted among rural Ugandans found 
that T cell activation was not an independent predictor of HIV disease progression 87. 
Thus future work should systematically evaluate what biomarkers and factors 
associate with faster disease progression in African cohorts in comparison to western 
cohorts. 
 
6.4 Subtype divergence and immunoregulatory T cell subsets 
Invariant natural killer T cells direct innate and adaptive cell responses to an infection 
through their production of immunoregulatory and activating cytokines. Regulatory T 
   35
(Treg) cells modulate immune responses to infection through production of cytokines 
or directly by activating apoptotic and/or interruption of metabolic pathways. We thus 
aimed to investigate if distribution of these cell subsets associated with differential 
immunopathogenesis of subtype A and D infection. We found that HIV-1 subtype D 
infected Ugandans had a significantly lower level of iNKT cells than HIV uninfected 
Ugandans (Paper II, Fig. 1b). In contrast, subtype A subjects had a significantly lower 
level of Tregs than either subtype D infected or uninfected subjects, despite both 
subtypes showing Treg loss (Paper II, Fig. 1d). Interestingly, only in subtype A 
infection were correlations observed between total CD4 T cell function and iNKT cell 
frequency, when stimulated with SEB (positive association, Paper II, Fig. 1e, f and g) 
and CMV (inverse association, Paper II, Fig. 1h, i and j). The positive correlation of 
CD4 T cell function to iNKT cell levels held even when it was taken by single 
cytokine expression. There were no associations of iNKT cell levels to Treg levels, 
CD4 T cell absolute count or viral load in either subtype.  
 
More significant iNKT cell loss in subtype D compared to subtype A infection despite 
being at the same stage of infection may contribute to the divergence in 
immunopathogenesis described in Uganda. Selective loss of immunoregulatory iNKT 
cells and dysfunction of remaining cells has previously been documented in HIV 
infection 288, 365. Interestingly, a study of HIV-1 and the less virulent HIV-2 infection 
found loss of iNKT cells in HIV-1, HIV-1/2 and viraemic HIV-2 infected individuals 
compared to uninfected controls, suggesting that preservation of iNKT cells associated 
with less immunopathogenesis in this African cohort 366. iNKT cells were also more 
activated in viraemic compared to aviraemic HIV-2 infected individuals, and activation 
levels correlated with markers of disease progression. When these findings are taken 
together with preservation of iNKT cells in subtype A infection that associated with 
general polyfunctionality of CD4 T cells, it suggests that iNKT cell levels, and 
possibly function are important for protection against HIV disease. The loss of Tregs 
could mean less suppression of general immune responses 174, 181 and thus better 
clinical outcomes. 
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Of note, preservation/reconstitution of CD4 T cell ability to produce IL-2 has been 
associated with control of HIV viraemia 367, is a potential correlate of immune 
protection from HIV acquisition 255 and leads to improved NK cell function 368. Levels 
of polyfunctional CD4 T cells (IFNγ and IL-2 positive) associate inversely to viral load 
in HIV-TB coinfection, adding to the body of knowledge on the importance of these 
cells in the immunopathogenesis of HIV infection 369. While it is not clear why our 
findings were independent of CD4 T cell counts and viral load, it is possible that the 
defects we describe are established early in infection. Proulx et al show that iNKT 
cells are dysregulated quite early in infection, with differential influence of transmitted 
founder virus isolates on iNKT cell activity in female genital mucosa 282. Taken 
together, this data shows differences in immunoregulatory T cell levels, adaptive T cell 
responses and associations with viral subtype that may contribute to differential 
pathogenesis of HIV-1 subtype A and D infections.  
 
6.5 Innate-like terminal effector CD8 T cells expand in HIV infection  
CD8 T cells utilize a range of effector functions to combat viral infections, including 
cytolysis and effects mediated by cytokines and chemokines, utilizing antigen-
specific T cell receptor recognition of antigen-bearing MHC in a restricted manner. 
However, CD8 T cells have been shown to develop innate-like characteristics in the 
context of chronic infection 370. In this study we hypothesized that late-stage 
differentiation of CD8 T cells may be associated with transcriptional changes that 
support innate-like effector functions in the T cell compartment. We found that indeed 
a αβ TCR bearing CD8 T cell population expressing the FcγRIIIA expands in 
chronic untreated HIV-1 infection, that they were highly activated (Paper IV, Fig. 
1b-d) and persisted even with ART (Paper IV, Fig. 1g). The activation of this subset 
associated with plasma markers of HIV-driven systemic immune activation (Paper 
IV, Fig. 1i). Phenotypically, FcγRIIIA+ CD8 T cells were distinct from FcγRIIIA- 
CD8 T cells as they were terminally differentiated effector cells that expressed 
perforin and NKG2D expression while not expressing CD161 (Paper IV, Fig. 2a-c), 
and were thus less likely to be invariant T cells. The significant upregulation of the 
transcription factor Helios, at the protein level, distinguished FcγRIIIA+ CD8 T cells 
from FcγRIIIA- CD8 T cells and NK cells (Paper IV, Fig. 2d). Interestingly, when 
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we assessed KIR expression we found that FcγRIIIA+ CD8 T cells from HIV-
infected persons had a similar expression pattern to NK cells, while they were 
intermediate between FcγRIIIA- CD8 T cells and NK cells in healthy donors (Paper 
IV, Fig. 2e). Transcriptomic analysis confirmed that the level of Helios gene IKZF2 
and IL-7Rα gene transcription distinguished FcγRIIIA+ from FcγRIIIA- CD8 T cells 
and NK cells, while transcript levels of the NK cell-associated receptor NKp80 gene 
KLRF1 was similar between FcγRIIIA+ CD8 T cells and CD56dim NK cells (Paper 
IV, Fig. 3). Furthermore, the capacity of FcγRIIIA+ CD8 T cells to mediate HIV-1-
specific ADCC was similar to that of FcγRIIIA+ NK cells on a per cell basis (Paper 
IV, Fig. 4c). Thus these late-stage effector T cells acquire FcγRIIIA expression in 
HIV-1 infected individuals and use it to mediate HIV-specific ADCC, a function 
normally associated with NK cells. Functional diversification of adaptive CD8 T 
cells may be important as therapeutic strategies evolve to include antibody-mediated 
mechanisms to eliminate HIV-1 reservoirs.  
 
FcγRIIIA+ CD8 T cells expansion coincident with bulk CD8 T cell population 
expansion suggests a concomitant response to the chronic uncontrolled viral 
replication. In some murine models, bystander activated memory CD8 T cells can 
recognize and clear pathogens in a TCR-independent fashion (NKG2D 371 and IFNγ 
plus GrzB 372). In another murine model, innate-like memory CD8 T cells respond to 
inflammasome-generated cytokine by promoting antimicrobial resistance in lymph 
nodes while inhibiting systemic spread 373. Jacomet et al describe a phenotypically 
similar population of ‘innate/memory-like’ CD8 T cells in both healthy adults and 
cord blood and hypothesize that they would expand in infection 374. Similarly, 
FcγRIIIA+ CD8 T cells maintained protein expression of T-bet and Eomes while 
downregulating CD127, which confirms that they are terminally differentiated 
effector cells 375. The FcγRIIIA+ CD8 T cells we describe adopt a KIR profile 
similar to NK cells in HIV-1 infected subjects, and their activation associates with 
systemic immune activation, suggesting that they expand in response to infection. 
NK cell KIR profiles have been found to influence HIV immunopathogenesis 376. 
Previously, Eller et al found expansion of polyfunctional KIR3DL1+ CD56dim NK 
cells in chronic untreated HIV-1 infected Ugandans who expressed the appropriate 
HLA-B ligand 214. CD8 T cells from healthy donors have been shown to express 
single activating or inhibitory receptors independent of their HLA ligands and NK 
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cell inhibitory receptors 377. That FcγRIIIA+ CD8 T cells express multiple KIRs may 
be a feature of this subset, with the similarity to NK cells being a function of viral 
replication. The conditions in vivo during HIV-1 infection thus seem to drive not 
only an expansion of these cells, but also expression of surface receptors beyond 
FcγRIIIA normally associated with NK cells.  
 
At gene level, the FcγRIIIA+ CD8 T cells appear to have a transcriptional program 
intermediate between late-stage effector CD8 T cells lacking FcγRIIIA and CD56dim 
NK cell expressing FcγRIIIA. The FcγRIIIA+ CD8 T cells displayed high expression 
of grzB and granulysin, maintained expression of IL-21R but with very low 
expression of IL-7Rα. It is thus possible that these effector cells are maintained by 
IL-7 independent mechanisms, such as by IL-21 378, 379, as they remain stable over 12 
months of ART. Consistent with upregulation of surface KIR expression in this 
subset in HIV infection, genes for other NK cell-associated receptors were also 
upregulated. Most interestingly, the KLRF1 gene, which encodes the activating 
receptor NKp80 was expressed at similar levels as in CD56dim NK cells. NKp80 has 
recently been shown to associate with the development and maturation of fully 
functional NK cells in secondary lymphoid tissue in response to signals from DC in 
addition to cytokines such as IL-15 380. We hypothesize that NKp80 could be playing 
a similar role here. It is also possible that, like is seen with NK cells, FcγRIIIA+ CD8 
T cells utilize NKp80 to foster mutual activation of the CD8 T cells and 
monocytes/macrophages for improved viral control 381.  
 
In addition, the FcγRIIIA+ CD8 T cells displayed high expression of the 
transcription factor Helios both at the protein and gene levels, as well as a modestly 
lower expression of the transcription factor Eomes. At the protein level Eomes 
expression in the FcγRIIIA+ CD8 T cells appeared normal, which was consistent 
with previous studies 374. Helios has been shown to mark out T cells that have been 
activated and are proliferating 382. Possibly, then, the distinctive transcription factor 
pattern contributes to sustaining FcγRIIIA+ CD8 T cell expansion in HIV-1 infected 
individuals. It would also be interesting to establish if they can be activated and 
maintained by other means, such as cytokine and natural cytotoxicity receptors 371, 
372, 374.  
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The expansion of FcγRIIIA+ CD8 T cells we describe is reminiscent of CD8 T cells 
with a similar phenotype in HCV-infected patients 370. The chronic nature of these 
infections with rapid viral replication and high mutation rates, leads to selection of 
epitope immune escape variants. The FcγRIIIA+ CD8 T cells display a memory 
phenotype of expanded antigen-specific T cells 383, 384 but whose epitopes possibly 
mutated, and thus the new biological characteristics including additional mechanisms 
to trigger effector activity may be a way to repurpose this subset to contribute to the 
immune response. It is intriguing that in murine models innate-like memory CD8 T 
cells were important for the immune response to both viral and bacterial infections, 
particularly in the early response. More studies exploring the role of the FcγRIIIA+ 
CD8 T cells in reactivated and opportunistic infections in the context of HIV 
infection are warranted. The ADCC activity of these cells could perhaps be 
harnessed for HIV preventive, therapeutic and cure research 99, 225.  
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7. CONCLUDING REMARKS 
This thesis aimed to investigate what role innate immune cellular subsets play in the 
immunopathogenesis of chronic untreated HIV-1 infection in Ugandans. We also 
investigated cellular differences between subtype A and D infection in order to 
elucidate differential immunopathogenesis. A number of lymphocyte subsets were 
studied including NK cells, iNKT cells, regulatory T cell subsets and CD8 T cells 
exhibiting innate-like ADCC activity. Furthermore, the distribution of lymphocyte 
subsets and reference ranges were determined for the Ugandan population. We found 
altered and impaired phenotypes and functions in HIV infection consistent with HIV-
driven immune dysregulation, although we could not rule out contributions from 
other coinfections not assessed in our studies. The impairments of NK cells and 
iNKT cells may contribute to the accelerated immunopathogenesis of subtype D 
infection. It is interesting that cytokines such as IL-12 and IL-18 can, at least 
hypothetically, activate most of the cell subsets described here, and yet we show 
impaired cytokine responses in NK cells. In addition, some CD8 T cells, in HIV 
infected donors, develop the capacity to perform ADCC and mediate HIV-specific 
immunity in this way thus possibly adding to the functional repertoire employed 
against HIV. Further work should be done to evaluate phenotype and function of 
these cells with different stimuli, particularly in the context of subtype D infection. 
 
   41
8 ACKNOWLEDGEMENTS 
I would like to start by thanking the Karolinska Institutet for the funding and opportunity to 
do this PhD. It has been a culmination of over four years of research and doctoral studies, 
accomplished in three continents. I would also like to thank the management of Makerere 
University Walter Reed Project and the US Military HIV Research Program for covering 
all additional costs, but most importantly for giving me the opportunity and allowing me the 
freedom to pursue these studies. Such opportunities do not come often and I feel very blessed 
to be the second recipient of the Swedish Ugandan Research Collaboration. Did I mention 
that Stockholm is one of the most beautiful cities on earth? 
To my main supervisor Johan K. Sandberg, to put it simply, tack! You took my raw mind 
and turned it into a scientific one. I have not only appreciated but also benefited from your 
vast experience, keen mind and attention to detail. I find myself checking fonts and formats 
automatically now, while thinking of publishable units . You have taught me, and taught 
me very well sir! The discussions of world events were a lovely bonus. 
To my co-supervisors: Michael A. Eller, thank you for introducing me to the fun of flow 
cytometry. Your mentorship, encouragement and time have been invaluable, and it has been a 
pleasure to walk in your footsteps. Weebale nnyo ssebo. I am looking forward to continued 
collaboration. Fred Wabwire-Mangen, thank you for all the encouragement and support, 
and for allowing me access to the protocols. Your knowledge and guidance as regards HIV 
research in Uganda is very much appreciated. 
To my mentor Robert Tweyongyere, I do not know what you saw in a young undergraduate, 
but all your advice and support has paid off. Thank you very much! 
MUWRP team: Monica and Dr. Hannah, I am very grateful for the never-ending support. 
Arthur N, thank you for catering to the logistics of study. FK, grants here we come! Olivia, 
ebyaffe obitegeera! Ronald K, Irene B, Irene K, Lillian Z and Patricia M, thank you for 
making sure I didn’t get stuck at some airport or hotel. Albert, hail Teamviewer! Fatim, your 
friendship and advice has been invaluable, especially as regards the practicalities of being a 
wife and mother amidst serious scientific endeavour. Allan O, I appreciate the hours spent 
discussing ideas and interpretation of data. I officially hand over the baton to you. To the lab 
team, I appreciate you all. Let us do this! 
Mark de Souza, thank you for your faith in me, and affirming that this is possible to achieve. 
Britta Flach, where would I be without all your help and guidance with my MSc thesis? 
  42
To the Sandberg/Moll constellation, few communities are ever as truly multinational and 
multicultural like this one. I am going to miss the incredible ice cream and cake at group 
meetings and dinners. Remind me to treat everyone to a bar of Magnum the next time I am in 
Stockholm. Markus, thank you for being the other supervisor. I am glad you get to visit 
Kampala. Susanna, you and Filip are some of the nicest people I have met on this journey. 
Thank you for taking the time to introduce me to Stockholm and the practicalities of getting 
around. Joana, I am going to miss all the fun we had while I visited. We never got round to 
our dance date, but since you owe me a trip to Kampala… . Thank you for the interesting 
conversations on multiculturalism Sush. David, your advice on staining chemokine receptors 
was invaluable. Ed, Dom, Michal, here is to more conference lunches and dinners. Jean-
Baptiste, Caroline and Kerri, you are in great hands. 
To the Eller group (Margaret, Kerri and Matt), thank you for all your help and advice on 
projects, and for making me a part of the group while I spent time in Silver Springs. Leigh 
Anne, thank you for opening up your home to me! 
To Joan K and Christine N, what are the odds of meeting in an airport like we did? Thank 
you for being my family in Stockholm and for telling me where all the sales were. The 
Galleria and IKEA must surely miss us . 
To the learned friends, Benson, Peter, Bernard, Denis, Marc, Tina, Ebenezer! Who knew 
we would get here? We need to have another sitting! 
To my family, thank you for unconditional support, late evening drop offs and pick-ups, and 
for all the prayers, to mention but a few. To Mum Katale and Mum Mpererwe, I am the 
recipient of the rare blessing of two women who love me unconditionally, and take pride in 
every little success. Mukama abampeere omukisa! To The Klan, for what do we live… The 
inside jokes have kept me sane on many lonely days and nights. Mubutuufu, akugoba 
yakulaga ekkubo! Nancy, we have got this figured out. I could write more, but I would never 
hear the last of it . Dad, you would have been so proud! 
1 Tim 2:1 To my church family, especially Pastors Michael and Lucy, Christine, Peace, 
Harriet and Mum Flavia, thank you! May He who does not forget your good works do what 
He does best. 
To Arthur my love, best friend, confidante and greatest fan, you are love personified. You 
pushed me to pursue this PhD, and have patiently and lovingly endured my long absences. 
The common adage goes that behind every successful man… well, true to your against the 
   43
mould personality, we have done the opposite! Njogere kki ssebo okujjako okukwebaza?! I 
cannot wait for the next part of our journey. Together we will scale the heights! The very 
pleasant surprise that is Samuel has made the last few months of this journey a unique 
challenge . But who can give up such a smile; such a blessing?  
Last and most important is Abba; thank you. In you I live, move and have my being! 
 

   45
9 REFERENCES 
1. CDC. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men--New 
York City and California.  MMWR Morbidity and mortality weekly report. 1981/07/03 ed: 
Center for Disease Control; 1981. p. 305-8. 
2. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus 
from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 
220(4599): 868-71. 
3. Klatzmann D, Barre-Sinoussi F, Nugeyre MT, et al. Selective tropism of 
lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science 1984; 
225(4657): 59-63. 
4. Dalgleish AG, Beverley PCL, Clapham PR, Crawford DH, Greaves MF, Weiss RA. 
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. 
Nature 1984; 312(5996): 763-7. 
5. Goedert JJ, Sarngadharan MG, Biggar RJ, et al. Determinants of retrovirus (HTLV-III) 
antibody and immunodeficiency conditions in homosexual men. Lancet (London, England) 
1984; 2(8405): 711-6. 
6. Coffin J, Haase A, Levy JA, et al. What to call the AIDS virus? Nature 1986; 
321(6065): 10. 
7. UBOS. National Housing and Population Census 2014. Colville Street, Kampala: 
Uganda Bureau of Statistics; 2014. 
8. UAC. HIV and AIDS UGANDA COUNTRY PROGRESS REPORT; 2013. In: 
Commission UA, editor. Ntinda. Nakawa Division, Kampala: Uganda AIDS Commision; 
2014. 
9. Serwadda D, Mugerwa RD, Sewankambo NK, et al. Slim disease: a new disease in 
Uganda and its association with HTLV-III infection. Lancet (London, England) 1985; 
2(8460): 849-52. 
10. Kamradt T, Niese D, Vogel F. Slim disease (AIDS). Lancet (London, England) 1985; 
2(8469-70): 1425. 
11. Clavel F, Guetard D, Brun-Vezinet F, et al. Isolation of a new human retrovirus from 
West African patients with AIDS. Science 1986; 233(4761): 343-6. 
12. Clavel F, Guyader M, Guetard D, Salle M, Montagnier L, Alizon M. Molecular cloning 
and polymorphism of the human immune deficiency virus type 2. Nature 1986; 324(6098): 
691-5. 
13. WHO. HIV/AIDS. July 2015 2015 (accessed 19Aug2015 2015). 
14. Faria NR, Rambaut A, Suchard MA, et al. The early spread and epidemic ignition of 
HIV-1 in human populations. Science 2014; 346(6205): 56-61. 
15. CDC. A cluster of Kaposi's sarcoma and Pneumocystis carinii pneumonia among 
homosexual male residents of Los Angeles and Orange Counties, California.  MMWR 
Morbidity and mortality weekly report. 1982/06/18 ed; 1982. p. 305-7. 
16. Auerbach DM, Darrow WW, Jaffe HW, Curran JW. Cluster of cases of the acquired 
immune deficiency syndrome. Patients linked by sexual contact. The American journal of 
medicine 1984; 76(3): 487-92. 
  46
17. Chaisson RE, Moss AR, Onishi R, Osmond D, Carlson JR. Human immunodeficiency 
virus infection in heterosexual intravenous drug users in San Francisco. American journal of 
public health 1987; 77(2): 169-72. 
18. Desmyter J. Needlestick transmission of HTLV-III from a patient infected in Africa. 
Lancet (London, England) 1984; 2(8416): 1376-7. 
19. CDC. Pneumocystis carinii pneumonia among persons with hemophilia A.  MMWR 
Morbidity and mortality weekly report. 1982/07/16 ed; 1982. p. 365-7. 
20. CDC. Unexplained immunodeficiency and opportunistic infections in infants--New 
York, New Jersey, California.  MMWR Morbidity and mortality weekly report. 1982/12/17 
ed; 1982. p. 665-7. 
21. Ziegler JB, Cooper DA, Johnson RO, Gold J. Postnatal transmission of AIDS-
associated retrovirus from mother to infant. Lancet (London, England) 1985; 1(8434): 896-8. 
22. Curran JW, Morgan WM, Starcher ET, Hardy AM, Jaffe HW. Epidemiological trends 
of AIDS in the United States. Cancer research 1985; 45(9 Suppl): 4602s-4s. 
23. Glauser MP, Francioli P. Clinical and epidemiological survey of acquired immune 
deficiency syndrome in Europe. European journal of clinical microbiology 1984; 3(1): 55-8. 
24. Piot P, Quinn TC, Taelman H, et al. Acquired immunodeficiency syndrome in a 
heterosexual population in Zaire. Lancet (London, England) 1984; 2(8394): 65-9. 
25. Montagnier L. Historical essay. A history of HIV discovery. Science 2002; 298(5599): 
1727-8. 
26. Gallo RC. Historical essay. The early years of HIV/AIDS. Science 2002; 298(5599): 
1728-30. 
27. Wain-Hobson S, Alizon M, Montagnier L. Relationship of AIDS to other retroviruses. 
Nature 1985; 313(6005): 743. 
28. Alizon M, Sonigo P, Barre-Sinoussi F, et al. Molecular cloning of lymphadenopathy-
associated virus. Nature 1984; 312(5996): 757-60. 
29. Marx JL. AIDS virus genomes. Science 1985; 227(4686): 503. 
30. Montagnier L. Lymphadenopathy-associated virus: from molecular biology to 
pathogenicity. Annals of internal medicine 1985; 103(5): 689-93. 
31. Montagnier L, Clavel F, Krust B, et al. Identification and antigenicity of the major 
envelope glycoprotein of lymphadenopathy-associated virus. Virology 1985; 144(1): 283-9. 
32. Wain-Hobson S, Sonigo P, Danos O, Cole S, Alizon M. Nucleotide sequence of the 
AIDS virus, LAV. Cell 1985; 40(1): 9-17. 
33. Ratner L, Haseltine W, Patarca R, et al. Complete nucleotide sequence of the AIDS 
virus, HTLV-III. Nature 1985; 313(6000): 277-84. 
34. Dowbenko DJ, Bell JR, Benton CV, et al. Bacterial expression of the acquired 
immunodeficiency syndrome retrovirus p24 gag protein and its use as a diagnostic reagent. 
Proceedings of the National Academy of Sciences of the United States of America 1985; 
82(22): 7748-52. 
35. Handsfield HH, Wandell M, Goldstein L, Shriver K. Screening and diagnostic 
performance of enzyme immunoassay for antibody to lymphadenopathy-associated virus. 
Journal of clinical microbiology 1987; 25(5): 879-84. 
   47
36. AMA. Consensus conference: The impact of routine HTLV-III antibody testing of 
blood and plasma donors on public health. In: CDC Na, editor. Jama. 1986/10/03 ed: 
American Medical Association; 1986. p. 1778-83. 
37. Yarchoan R, Klecker RW, Weinhold KJ, et al. Administration of 3'-azido-3'-
deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-
related complex. Lancet (London, England) 1986; 1(8481): 575-80. 
38. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in 
the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-
controlled trial. The New England journal of medicine 1987; 317(4): 185-91. 
39. Landesman SH, Ginzburg HM, Weiss SH. The AIDS epidemic. The New England 
journal of medicine 1985; 312(8): 521-5. 
40. Carswell JW. Impact of AIDS in the developing world. British medical bulletin 1988; 
44(1): 183-202. 
41. Weiss RA. Retrovirus classification and cell interactions. The Journal of antimicrobial 
chemotherapy 1996; 37 Suppl B: 1-11. 
42. Hemelaar J. The origin and diversity of the HIV-1 pandemic. Trends in molecular 
medicine 2012; 18(3): 182-92. 
43. Peeters M, D’Arc M, Delaporte E. The origin and diversity of human retroviruses. 
AIDS reviews 2014; 16(1): 23-34. 
44. Bieniasz PD. An overview of intracellular interactions between immunodeficiency 
viruses and their hosts. AIDS 2012; 26(10): 1243-54. 
45. Lihana RW, Ssemwanga D, Abimiku A, Ndembi N. Update on HIV-1 diversity in 
Africa: a decade in review. AIDS reviews 2012; 14(2): 83-100. 
46. Crowe S, Mills J, McGrath MS. Quantitative immunocytofluorographic analysis of 
CD4 surface antigen expression and HIV infection of human peripheral blood 
monocyte/macrophages. AIDS research and human retroviruses 1987; 3(2): 135-45. 
47. Campbell JH, Hearps AC, Martin GE, Williams KC, Crowe SM. The importance of 
monocytes and macrophages in HIV pathogenesis, treatment, and cure. AIDS 2014; 28(15): 
2175-87. 
48. Ganser-Pornillos BK, Yeager M, Sundquist WI. The structural biology of HIV 
assembly. Current opinion in structural biology 2008; 18(2): 203-17. 
49. Wilen CB, Tilton JC, Doms RW. HIV: cell binding and entry. Cold Spring Harbor 
perspectives in medicine 2012; 2(8). 
50. Freed EO. HIV-1 assembly, release and maturation. Nature reviews Microbiology 
2015; 13(8): 484-96. 
51. Mohammadi P, Ciuffi A, Beerenwinkel N. Dynamic models of viral replication and 
latency. Current opinion in HIV and AIDS 2015; 10(2): 90-5. 
52. Holmes M, Zhang F, Bieniasz PD. Single-Cell and Single-Cycle Analysis of HIV-1 
Replication. PLoS pathogens 2015; 11(6): e1004961. 
53. Chen HY, Di Mascio M, Perelson AS, Ho DD, Zhang L. Determination of virus burst 
size in vivo using a single-cycle SIV in rhesus macaques. Proceedings of the National 
Academy of Sciences of the United States of America 2007; 104(48): 19079-84. 
  48
54. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in 
lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362(6418): 355-8. 
55. Haase AT. Perils at mucosal front lines for HIV and SIV and their hosts. Nature 
reviews Immunology 2005; 5(10): 783-92. 
56. Robb ML, Eller LA, Kibuuka H, et al. Prospective Study of Acute HIV-1 Infection in 
Adults in East Africa and Thailand. The New England journal of medicine 2016; 374(22): 
2120-30. 
57. Fraser C, Lythgoe K, Leventhal GE, et al. Virulence and pathogenesis of HIV-1 
infection: an evolutionary perspective. Science 2014; 343(6177): 1243727. 
58. Stacey AR, Norris PJ, Qin L, et al. Induction of a striking systemic cytokine cascade 
prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to 
more modest and delayed responses in acute hepatitis B and C virus infections. Journal of 
virology 2009; 83(8): 3719-33. 
59. Ananworanich J, Sacdalan CP, Pinyakorn S, et al. Virological and immunological 
characteristics of HIV-infected individuals at the earliest stage of infection. Journal of virus 
eradication 2016; 2: 43-8. 
60. Ananworanich J, Schuetz A, Vandergeeten C, et al. Impact of multi-targeted 
antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV 
infection. PloS one 2012; 7(3): e33948. 
61. Vieillard V, Strominger JL, Debre P. NK cytotoxicity against CD4+ T cells during 
HIV-1 infection: a gp41 peptide induces the expression of an NKp44 ligand. Proceedings of 
the National Academy of Sciences of the United States of America 2005; 102(31): 10981-6. 
62. Fraietta JA, Mueller YM, Yang G, et al. Type I interferon upregulates Bak and 
contributes to T cell loss during human immunodeficiency virus (HIV) infection. PLoS 
pathogens 2013; 9(10): e1003658. 
63. Finkel TH, Tudor-Williams G, Banda NK, et al. Apoptosis occurs predominantly in 
bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. 
Nat Med 1995; 1(2): 129-34. 
64. Gougeon ML, Lecoeur H, Dulioust A, et al. Programmed cell death in peripheral 
lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and 
CD8 T cells correlates with lymphocyte activation and with disease progression. Journal of 
immunology 1996; 156(9): 3509-20. 
65. Pawig L, Klasen C, Weber C, Bernhagen J, Noels H. Diversity and Inter-Connections 
in the CXCR4 Chemokine Receptor/Ligand Family: Molecular Perspectives. Frontiers in 
immunology 2015; 6: 429. 
66. Cooper A, Garcia M, Petrovas C, Yamamoto T, Koup RA, Nabel GJ. HIV-1 causes 
CD4 cell death through DNA-dependent protein kinase during viral integration. Nature 2013; 
498(7454): 376-9. 
67. Jiang W, Younes SA, Funderburg NT, et al. Cycling memory CD4+ T cells in HIV 
disease have a diverse T cell receptor repertoire and a phenotype consistent with bystander 
activation. Journal of virology 2014; 88(10): 5369-80. 
68. Younes SA, Freeman ML, Mudd JC, et al. IL-15 promotes activation and expansion of 
CD8+ T cells in HIV-1 infection. The Journal of clinical investigation 2016; 126(7): 2745-
56. 
   49
69. Benecke A, Gale M, Jr., Katze MG. Dynamics of innate immunity are key to chronic 
immune activation in AIDS. Current opinion in HIV and AIDS 2012; 7(1): 79-85. 
70. Hatano H. Immune activation and HIV persistence: considerations for novel therapeutic 
interventions. Current opinion in HIV and AIDS 2013; 8(3): 211-6. 
71. Piatak M, Jr., Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all 
stages of infection determined by competitive PCR. Science 1993; 259(5102): 1749-54. 
72. Piatak M, Jr., Saag MS, Yang LC, et al. Determination of plasma viral load in HIV-1 
infection by quantitative competitive polymerase chain reaction. AIDS 1993; 7 Suppl 2: S65-
71. 
73. Pinching AJ, Helbert M, Peddle B, et al. Clinical experience with zidovudine for 
patients with acquired immune deficiency syndrome and acquired immune deficiency 
syndrome-related complex. The Journal of infection 1989; 18 Suppl 1: 33-40. 
74. Rooke R, Tremblay M, Soudeyns H, et al. Isolation of drug-resistant variants of HIV-1 
from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study 
Group. AIDS 1989; 3(7): 411-5. 
75. Richman DD. HIV drug resistance. AIDS research and human retroviruses 1992; 8(6): 
1065-71. 
76. Doran CM. New approaches to using antiretroviral therapy for the management of HIV 
Infection. The Annals of pharmacotherapy 1997; 31(2): 228-36. 
77. Fox JL. AIDS researchers emphasize new drug combinations. Nature biotechnology 
1997; 15(3): 215. 
78. Lundgren JD, Babiker AG, Gordin F, et al. Initiation of Antiretroviral Therapy in Early 
Asymptomatic HIV Infection. The New England journal of medicine 2015; 373(9): 795-807. 
79. Phillips AN, Gazzard B, Gilson R, et al. Rate of AIDS diseases or death in HIV-
infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS 2007; 
21(13): 1717-21. 
80. Zeng M, Paiardini M, Engram JC, et al. Critical role of CD4 T cells in maintaining 
lymphoid tissue structure for immune cell homeostasis and reconstitution. Blood 2012; 
120(9): 1856-67. 
81. UNAIDS. How AIDS changed everything Geneva, Switzerland: UNAIDS, 2015. 
82. UNAIDS. Press Release: 2014 Gap Report. In: UNAIDS, editor. Geneva, Switzerland: 
UNAIDS; 2014. 
83. Esbjornsson J, Mansson F, Kvist A, et al. Inhibition of HIV-1 disease progression by 
contemporaneous HIV-2 infection. The New England journal of medicine 2012; 367(3): 224-
32. 
84. de Silva TI, Cotten M, Rowland-Jones SL. HIV-2: the forgotten AIDS virus. Trends in 
microbiology 2008; 16(12): 588-95. 
85. Amornkul PN, Karita E, Kamali A, et al. Disease progression by infecting HIV-1 
subtype in a seroconverter cohort in sub-Saharan Africa. AIDS 2013. 
86. Ssemwanga D, Nsubuga RN, Mayanja BN, et al. Effect of HIV-1 subtypes on disease 
progression in rural Uganda: a prospective clinical cohort study. PloS one 2013; 8(8): 
e71768. 
  50
87. Eller MA, Opollo MS, Liu M, et al. HIV Type 1 Disease Progression to AIDS and 
Death in a Rural Ugandan Cohort Is Primarily Dependent on Viral Load Despite Variable 
Subtype and T-Cell Immune Activation Levels. The Journal of infectious diseases 2015; 
211(10): 1574-84. 
88. Taylor BS, Hammer SM. The challenge of HIV-1 subtype diversity. The New England 
journal of medicine 2008; 359(18): 1965-6. 
89. Pant Pai N, Shivkumar S, Cajas JM. Does genetic diversity of HIV-1 non-B subtypes 
differentially impact disease progression in treatment-naive HIV-1-infected individuals? A 
systematic review of evidence: 1996-2010. Journal of acquired immune deficiency 
syndromes 2012; 59(4): 382-8. 
90. Kyeyune F, Nankya I, Metha S, et al. Treatment failure and drug resistance is more 
frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study 
period. AIDS 2013; 27(12): 1899-909. 
91. Leeansyah E, Malone DF, Anthony DD, Sandberg JK. Soluble biomarkers of HIV 
transmission, disease progression and comorbidities. Current opinion in HIV and AIDS 2013; 
8(2): 117-24. 
92. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic 
disease. Lancet (London, England) 2013; 382(9903): 1525-33. 
93. Costagliola D. Demographics of HIV and aging. Current opinion in HIV and AIDS 
2014; 9(4): 294-301. 
94. Siegfried N, Muller M, Deeks JJ, Volmink J. Male circumcision for prevention of 
heterosexual acquisition of HIV in men. The Cochrane database of systematic reviews 2009; 
(2): CD003362. 
95. Ledikwe JH, Nyanga RO, Hagon J, Grignon JS, Mpofu M, Semo BW. Scaling-up 
voluntary medical male circumcision - what have we learned? HIV/AIDS (Auckland, NZ) 
2014; 6: 139-46. 
96. Esparza J. A brief history of the global effort to develop a preventive HIV vaccine. 
Vaccine 2013; 31(35): 3502-18. 
97. Excler JL, Robb ML, Kim JH. Prospects for a Globally Effective HIV-1 Vaccine. 
American journal of preventive medicine 2015; 49(6 Suppl 4): S307-18. 
98. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and 
AIDSVAX to prevent HIV-1 infection in Thailand. The New England journal of medicine 
2009; 361(23): 2209-20. 
99. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 
vaccine efficacy trial. The New England journal of medicine 2012; 366(14): 1275-86. 
100. Cox AP, Foss AM, Shafer LA, et al. Attaining realistic and substantial reductions in 
HIV incidence: model projections of combining microbicide and male circumcision 
interventions in rural Uganda. Sexually transmitted infections 2011; 87(7): 635-9. 
101. UN. World Population Prospects: The 2015 Revision, Key Findings and Advance 
Tables. Geneva: United Nations, Department of Economic and Social affairs, 2015. 
102. Cao X. Self-regulation and cross-regulation of pattern-recognition receptor signalling in 
health and disease. Nature reviews Immunology 2016; 16(1): 35-50. 
   51
103. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune 
defenses. Clinical microbiology reviews 2009; 22(2): 240-73, Table of Contents. 
104. Netea MG, Latz E, Mills KH, O'Neill LA. Innate immune memory: a paradigm shift in 
understanding host defense. Nature immunology 2015; 16(7): 675-9. 
105. Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic reactivity of 
mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of 
effector cells. International journal of cancer 1975; 16(2): 230-9. 
106. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid 
cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. 
International journal of cancer 1975; 16(2): 216-29. 
107. Beziat V, Duffy D, Quoc SN, et al. CD56brightCD16+ NK cells: a functional 
intermediate stage of NK cell differentiation. Journal of immunology 2011; 186(12): 6753-
61. 
108. Shifrin N, Raulet DH, Ardolino M. NK cell self tolerance, responsiveness and missing 
self recognition. Seminars in immunology 2014; 26(2): 138-44. 
109. Jost S, Altfeld M. Control of human viral infections by natural killer cells. Annual 
review of immunology 2013; 31: 163-94. 
110. Cichocki F, Sitnicka E, Bryceson YT. NK cell development and function--plasticity 
and redundancy unleashed. Seminars in immunology 2014; 26(2): 114-26. 
111. Sun JC, Lanier LL. NK cell development, homeostasis and function: parallels with 
CD8(+) T cells. Nature reviews Immunology 2011; 11(10): 645-57. 
112. Huntington ND, Legrand N, Alves NL, et al. IL-15 trans-presentation promotes human 
NK cell development and differentiation in vivo. The Journal of experimental medicine 2009; 
206(1): 25-34. 
113. Bjorkstrom NK, Riese P, Heuts F, et al. Expression patterns of NKG2A, KIR, and 
CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell 
education. Blood 2010; 116(19): 3853-64. 
114. Montaldo E, Vacca P, Moretta L, Mingari MC. Development of human natural killer 
cells and other innate lymphoid cells. Seminars in immunology 2014; 26(2): 107-13. 
115. Cooper MA, Colonna M, Yokoyama WM. Hidden talents of natural killers: NK cells in 
innate and adaptive immunity. EMBO reports 2009; 10(10): 1103-10. 
116. DeGottardi MQ, Okoye AA, Vaidya M, et al. Effect of Anti-IL-15 Administration on T 
Cell and NK Cell Homeostasis in Rhesus Macaques. Journal of immunology 2016; 197(4): 
1183-98. 
117. Parham P, Moffett A. Variable NK cell receptors and their MHC class I ligands in 
immunity, reproduction and human evolution. Nature reviews Immunology 2013; 13(2): 133-
44. 
118. Karre K. Natural killer cell recognition of missing self. Nature immunology 2008; 9(5): 
477-80. 
119. Strauss-Albee DM, Fukuyama J, Liang EC, et al. Human NK cell repertoire diversity 
reflects immune experience and correlates with viral susceptibility. Science translational 
medicine 2015; 7(297): 297ra115. 
  52
120. Eissens DN, Spanholtz J, van der Meer A, et al. Defining early human NK cell 
developmental stages in primary and secondary lymphoid tissues. PloS one 2012; 7(2): 
e30930. 
121. Campbell KS, Hasegawa J. Natural killer cell biology: An update and future directions. 
The Journal of allergy and clinical immunology 2013. 
122. Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK-cell 
cytokine and chemokine production by target cell recognition. Blood 2010; 115(11): 2167-76. 
123. Altfeld M, Fadda L, Frleta D, Bhardwaj N. DCs and NK cells: critical effectors in the 
immune response to HIV-1. Nature reviews Immunology 2011; 11(3): 176-86. 
124. Altfeld M, Gale M, Jr. Innate immunity against HIV-1 infection. Nature immunology 
2015; 16(6): 554-62. 
125. Schlums H, Cichocki F, Tesi B, et al. Cytomegalovirus infection drives adaptive 
epigenetic diversification of NK cells with altered signaling and effector function. Immunity 
2015; 42(3): 443-56. 
126. Beziat V, Liu LL, Malmberg JA, et al. NK cell responses to cytomegalovirus infection 
lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood 2013; 
121(14): 2678-88. 
127. Marras F, Bozzano F, Ascierto ML, De Maria A. Baseline and Dynamic Expression of 
Activating NK Cell Receptors in the Control of Chronic Viral Infections: The Paradigm of 
HIV-1 and HCV. Frontiers in immunology 2014; 5: 305. 
128. Bouzani M, Ok M, McCormick A, et al. Human NK cells display important antifungal 
activity against Aspergillus fumigatus, which is directly mediated by IFN-gamma release. 
Journal of immunology 2011; 187(3): 1369-76. 
129. Lauwerys BR, Renauld JC, Houssiau FA. Synergistic proliferation and activation of 
natural killer cells by interleukin 12 and interleukin 18. Cytokine 1999; 11(11): 822-30. 
130. Madera S, Sun JC. Cutting edge: stage-specific requirement of IL-18 for antiviral NK 
cell expansion. Journal of immunology 2015; 194(4): 1408-12. 
131. Vidal SM, Khakoo SI, Biron CA. Natural killer cell responses during viral infections: 
flexibility and conditioning of innate immunity by experience. Current opinion in virology 
2011; 1(6): 497-512. 
132. Morris MA, Ley K. Trafficking of natural killer cells. Current molecular medicine 
2004; 4(4): 431-8. 
133. Hamann I, Unterwalder N, Cardona AE, et al. Analyses of phenotypic and functional 
characteristics of CX3CR1-expressing natural killer cells. Immunology 2011; 133(1): 62-73. 
134. Donnelly RP, Loftus RM, Keating SE, et al. mTORC1-dependent metabolic 
reprogramming is a prerequisite for NK cell effector function. Journal of immunology 2014; 
193(9): 4477-84. 
135. Moretta A. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nature 
reviews Immunology 2002; 2(12): 957-64. 
136. Marcenaro E, Carlomagno S, Pesce S, Moretta A, Sivori S. NK/DC crosstalk in anti-
viral response. Advances in experimental medicine and biology 2012; 946: 295-308. 
   53
137. Foley B, Cooley S, Verneris MR, et al. Human cytomegalovirus (CMV)-induced 
memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to 
recipient CMV antigen. Journal of immunology 2012; 189(10): 5082-8. 
138. Foley B, Cooley S, Verneris MR, et al. Cytomegalovirus reactivation after allogeneic 
transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with 
potent function. Blood 2012; 119(11): 2665-74. 
139. Sun JC, Madera S, Bezman NA, Beilke JN, Kaplan MH, Lanier LL. Proinflammatory 
cytokine signaling required for the generation of natural killer cell memory. The Journal of 
experimental medicine 2012; 209(5): 947-54. 
140. Cerwenka A, Lanier LL. Natural killer cell memory in infection, inflammation and 
cancer. Nature reviews Immunology 2016; 16(2): 112-23. 
141. Groom JR. Moving to the suburbs: T-cell positioning within lymph nodes during 
activation and memory. Immunology and cell biology 2015; 93(4): 330-6. 
142. Pincetic A, Bournazos S, DiLillo DJ, et al. Type I and type II Fc receptors regulate 
innate and adaptive immunity. Nature immunology 2014; 15(8): 707-16. 
143. Bhat R, Watzl C. Serial killing of tumor cells by human natural killer cells--
enhancement by therapeutic antibodies. PloS one 2007; 2(3): e326. 
144. Bjorkstrom NK, Ljunggren HG, Sandberg JK. CD56 negative NK cells: origin, 
function, and role in chronic viral disease. Trends in immunology 2010; 31(11): 401-6. 
145. Eller MA, Eller LA, Ouma BJ, et al. Elevated natural killer cell activity despite altered 
functional and phenotypic profile in Ugandans with HIV-1 clade A or clade D infection. 
Journal of acquired immune deficiency syndromes 2009; 51(4): 380-9. 
146. Bryceson YT, Long EO. Line of attack: NK cell specificity and integration of signals. 
Current opinion in immunology 2008; 20(3): 344-52. 
147. van der Merwe PA, Dushek O. Mechanisms for T cell receptor triggering. Nature 
reviews Immunology 2011; 11(1): 47-55. 
148. Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR 
signalling. Nature reviews Immunology 2003; 3(12): 939-51. 
149. Venturi V, Rudd BD, Davenport MP. Specificity, promiscuity, and precursor frequency 
in immunoreceptors. Current opinion in immunology 2013; 25(5): 639-45. 
150. Malissen B, Bongrand P. Early T cell activation: integrating biochemical, structural, 
and biophysical cues. Annual review of immunology 2015; 33: 539-61. 
151. Sinclair LV, Rolf J, Emslie E, Shi YB, Taylor PM, Cantrell DA. Control of amino-acid 
transport by antigen receptors coordinates the metabolic reprogramming essential for T cell 
differentiation. Nature immunology 2013; 14(5): 500-8. 
152. Williams MA, Ravkov EV, Bevan MJ. Rapid culling of the CD4+ T cell repertoire in 
the transition from effector to memory. Immunity 2008; 28(4): 533-45. 
153. Kim C, Jay DC, Williams MA. Dynamic functional modulation of CD4+ T cell recall 
responses is dependent on the inflammatory environment of the secondary stimulus. PLoS 
pathogens 2014; 10(5): e1004137. 
154. Kared H, Camous X, Larbi A. T cells and their cytokines in persistent stimulation of 
the immune system. Current opinion in immunology 2014; 29: 79-85. 
  54
155. Tan JT, Ernst B, Kieper WC, LeRoy E, Sprent J, Surh CD. Interleukin (IL)-15 and IL-7 
jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not 
required for memory phenotype CD4+ cells. The Journal of experimental medicine 2002; 
195(12): 1523-32. 
156. Masopust D, Schenkel JM. The integration of T cell migration, differentiation and 
function. Nature reviews Immunology 2013; 13(5): 309-20. 
157. Thome JJ, Yudanin N, Ohmura Y, et al. Spatial map of human T cell 
compartmentalization and maintenance over decades of life. Cell 2014; 159(4): 814-28. 
158. Restifo NP, Gattinoni L. Lineage relationship of effector and memory T cells. Current 
opinion in immunology 2013; 25(5): 556-63. 
159. Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, 
compartmentalization and homeostasis. Nature reviews Immunology 2014; 14(1): 24-35. 
160. Thome JJC, Farber DL. Emerging concepts in tissue-resident T cells: lessons from 
humans. Trends in immunology 2015; 36(7): 428-35. 
161. Altin JG, Sloan EK. The role of CD45 and CD45-associated molecules in T cell 
activation. Immunology and cell biology 1997; 75(5): 430-45. 
162. Forster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and 
tolerance. Nature reviews Immunology 2008; 8(5): 362-71. 
163. Hendriks J, Gravestein LA, Tesselaar K, van Lier RAW, Schumacher TNM, Borst J. 
CD27 is required for generation and long-term maintenance of T cell immunity. Nature 
immunology 2000; 1(5): 433-40. 
164. Denoeud J, Moser M. Role of CD27/CD70 pathway of activation in immunity and 
tolerance. Journal of leukocyte biology 2011; 89(2): 195-203. 
165. Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C, Germain RN. 
Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-
dendritic cell interaction. Nature 2006; 440(7086): 890-5. 
166. Hickman HD, Li L, Reynoso GV, et al. Chemokines control naive CD8+ T cell 
selection of optimal lymph node antigen presenting cells. The Journal of experimental 
medicine 2011; 208(12): 2511-24. 
167. Camargo JF, Quinones MP, Mummidi S, et al. CCR5 expression levels influence 
NFAT translocation, IL-2 production, and subsequent signaling events during T lymphocyte 
activation. Journal of immunology 2009; 182(1): 171-82. 
168. Pulko V, Davies JS, Martinez C, et al. Human memory T cells with a naive phenotype 
accumulate with aging and respond to persistent viruses. Nature immunology 2016; 17(8): 
966-75. 
169. Effros RB, Boucher N, Porter V, et al. Decline in CD28+ T cells in centenarians and in 
long-term T cell cultures: a possible cause for both in vivo and in vitro immunosenescence. 
Experimental gerontology 1994; 29(6): 601-9. 
170. McElhaney JE, Effros RB. Immunosenescence: what does it mean to health outcomes 
in older adults? Current opinion in immunology 2009; 21(4): 418-24. 
171. Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4(+) T cells in immunity 
to viruses. Nature reviews Immunology 2012; 12(2): 136-48. 
   55
172. Edwards ES, Smith C, Khanna R. Phenotypic and transcriptional profile correlates with 
functional plasticity of antigen-specific CD4+ T cells. Immunology and cell biology 2014; 
92(2): 181-90. 
173. Hirahara K, Nakayama T. CD4+ T-cell subsets in inflammatory diseases: beyond the 
Th1/Th2 paradigm. International immunology 2016; 28(4): 163-71. 
174. Kerdiles Y, Ugolini S, Vivier E. T cell regulation of natural killer cells. The Journal of 
experimental medicine 2013; 210(6): 1065-8. 
175. Lin L, Ma C, Wei B, et al. Human NK cells licensed by killer Ig receptor genes have an 
altered cytokine program that modifies CD4+ T cell function. Journal of immunology 2014; 
193(2): 940-9. 
176. Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL. Cross-talk 
between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. 
Journal of immunology 2004; 173(6): 3716-24. 
177. Pallmer K, Oxenius A. Recognition and Regulation of T Cells by NK Cells. Frontiers 
in immunology 2016; 7: 251. 
178. Campbell DJ. Control of Regulatory T Cell Migration, Function, and Homeostasis. 
Journal of immunology 2015; 195(6): 2507-13. 
179. Lopez-Abente J, Correa-Rocha R, Pion M. Functional Mechanisms of Treg in the 
Context of HIV Infection and the Janus Face of Immune Suppression. Frontiers in 
immunology 2016; 7: 192. 
180. Liston A, Gray DHD. Homeostatic control of regulatory T cell diversity. Nature 
reviews Immunology 2014; 14(3): 154-65. 
181. Almeida AR, Zaragoza B, Freitas AA. Indexation as a novel mechanism of lymphocyte 
homeostasis: the number of CD4+CD25+ regulatory T cells is indexed to the number of IL-2-
producing cells. Journal of immunology 2006; 177(1): 192-200. 
182. Laidlaw BJ, Craft JE, Kaech SM. The multifaceted role of CD4(+) T cells in CD8(+) T 
cell memory. Nature reviews Immunology 2016; 16(2): 102-11. 
183. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal 
bridge between a CD4+ T-helper and a T-killer cell. Nature 1998; 393(6684): 474-8. 
184. Adam C, King S, Allgeier T, et al. DC-NK cell cross talk as a novel CD4+ T-cell-
independent pathway for antitumor CTL induction. Blood 2005; 106(1): 338-44. 
185. Finlay DK, Rosenzweig E, Sinclair LV, et al. PDK1 regulation of mTOR and hypoxia-
inducible factor 1 integrate metabolism and migration of CD8+ T cells. The Journal of 
experimental medicine 2012; 209(13): 2441-53. 
186. Bourgeois C, Rocha B, Tanchot C. A role for CD40 expression on CD8+ T cells in the 
generation of CD8+ T cell memory. Science 2002; 297(5589): 2060-3. 
187. Gerard A, Khan O, Beemiller P, et al. Secondary T cell-T cell synaptic interactions 
drive the differentiation of protective CD8+ T cells. Nature immunology 2013; 14(4): 356-63. 
188. Horenstein AL, Chillemi A, Zaccarello G, et al. A CD38/CD203a/CD73 ectoenzymatic 
pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. 
Oncoimmunology 2013; 2(9): e26246. 
  56
189. Deaglio S, Morra M, Mallone R, et al. Human CD38 (ADP-ribosyl cyclase) is a 
counter-receptor of CD31, an Ig superfamily member. Journal of immunology 1998; 160(1): 
395-402. 
190. Ausiello CM, la Sala A, Ramoni C, Urbani F, Funaro A, Malavasi F. Secretion of IFN-
gamma, IL-6, granulocyte-macrophage colony-stimulating factor and IL-10 cytokines after 
activation of human purified T lymphocytes upon CD38 ligation. Cellular immunology 1996; 
173(2): 192-7. 
191. Savarino A, Bottarel F, Malavasi F, Dianzani U. Role of CD38 in HIV-1 infection: an 
epiphenomenon of T-cell activation or an active player in virus/host interactions? AIDS 2000; 
14(9): 1079-89. 
192. Speiser DE, Migliaccio M, Pittet MJ, et al. Human CD8(+) T cells expressing HLA-DR 
and CD28 show telomerase activity and are distinct from cytolytic effector T cells. Eur J 
Immunol 2001; 31(2): 459-66. 
193. Imamichi H, Lempicki RA, Adelsberger JW, et al. The CD8+ HLA-DR+ T cells 
expanded in HIV-1 infection are qualitatively identical to those from healthy controls. Eur J 
Immunol 2012; 42(10): 2608-20. 
194. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell 
immunity. Nature reviews Immunology 2004; 4(5): 336-47. 
195. Chew GM, Fujita T, Webb GM, et al. TIGIT Marks Exhausted T Cells, Correlates with 
Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV 
Infection. PLoS pathogens 2016; 12(1): e1005349. 
196. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is 
associated with T-cell exhaustion and disease progression. Nature 2006; 443(7109): 350-4. 
197. Godfrey DI, Uldrich AP, McCluskey J, Rossjohn J, Moody DB. The burgeoning family 
of unconventional T cells. Nature immunology 2015; 16(11): 1114-23. 
198. Lanier LL. Shades of grey [mdash] the blurring view of innate and adaptive immunity. 
Nature reviews Immunology 2013; 13(2): 73-4. 
199. Vermijlen D, Prinz I. Ontogeny of Innate T Lymphocytes - Some Innate Lymphocytes 
are More Innate than Others. Frontiers in immunology 2014; 5: 486. 
200. Saeidi A, Ellegard R, Yong YK, et al. Functional role of mucosal-associated invariant 
T cells in HIV infection. Journal of leukocyte biology 2016. 
201. Vartabedian VF, Savage PB, Teyton L. The processing and presentation of lipids and 
glycolipids to the immune system. Immunological reviews 2016; 272(1): 109-19. 
202. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate activation 
scheme linked to diverse effector functions. Nature reviews Immunology 2013; 13(2): 101-
17. 
203. Paget C, Trottein F. Role of type 1 natural killer T cells in pulmonary immunity. 
Mucosal immunology 2013; 6(6): 1054-67. 
204. Juno JA, Keynan Y, Fowke KR. Invariant NKT cells: regulation and function during 
viral infection. PLoS pathogens 2012; 8(8): e1002838. 
205. Holzapfel KL, Tyznik AJ, Kronenberg M, Hogquist KA. Antigen-dependent versus -
independent activation of invariant NKT cells during infection. Journal of immunology 2014; 
192(12): 5490-8. 
   57
206. Opasawatchai A, Matangkasombut P. iNKT Cells and Their Potential Lipid Ligands 
during Viral Infection. Frontiers in immunology 2015; 6: 378. 
207. Simmons RP, Scully EP, Groden EE, et al. HIV-1 infection induces strong production 
of IP-10 through TLR7/9-dependent pathways. AIDS 2013; 27(16): 2505-17. 
208. Borrow P, Bhardwaj N. Innate immune responses in primary HIV-1 infection. Current 
opinion in HIV and AIDS 2008; 3(1): 36-44. 
209. Apps R, Del Prete GQ, Chatterjee P, et al. HIV-1 Vpu Mediates HLA-C 
Downregulation. Cell host & microbe 2016; 19(5): 686-95. 
210. Mohanram V, Skold AE, Bachle SM, Pathak SK, Spetz AL. IFN-alpha induces 
APOBEC3G, F, and A in immature dendritic cells and limits HIV-1 spread to CD4+ T cells. 
Journal of immunology 2013; 190(7): 3346-53. 
211. Tomescu C, Mavilio D, Montaner LJ. Lysis of HIV-1-infected autologous CD4+ 
primary T cells by interferon-alpha-activated NK cells requires NKp46 and NKG2D. AIDS 
2015; 29(14): 1767-73. 
212. Gooneratne SL, Richard J, Lee WS, Finzi A, Kent SJ, Parsons MS. Slaying the Trojan 
horse: natural killer cells exhibit robust anti-HIV-1 antibody-dependent activation and 
cytolysis against allogeneic T cells. Journal of virology 2015; 89(1): 97-109. 
213. Fauci AS, Mavilio D, Kottilil S. NK cells in HIV infection: paradigm for protection or 
targets for ambush. Nature reviews Immunology 2005; 5(11): 835-43. 
214. Eller MA, Koehler RN, Kijak GH, et al. Human immunodeficiency virus type 1 
infection is associated with increased NK cell polyfunctionality and higher levels of 
KIR3DL1+ NK cells in ugandans carrying the HLA-B Bw4 motif. Journal of virology 2011; 
85(10): 4802-11. 
215. Alter G, Rihn S, Walter K, et al. HLA class I subtype-dependent expansion of 
KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 
infection. Journal of virology 2009; 83(13): 6798-805. 
216. Alter G, Teigen N, Ahern R, et al. Evolution of innate and adaptive effector cell 
functions during acute HIV-1 infection. The Journal of infectious diseases 2007; 195(10): 
1452-60. 
217. Ahmad F, Hong HS, Jackel M, et al. High frequencies of polyfunctional CD8+ NK 
cells in chronic HIV-1 infection are associated with slower disease progression. Journal of 
virology 2014; 88(21): 12397-408. 
218. Tomescu C, Seaton KE, Smith P, et al. Innate activation of MDC and NK cells in high-
risk HIV-1-exposed seronegative IV-drug users who share needles when compared with low-
risk nonsharing IV-drug user controls. Journal of acquired immune deficiency syndromes 
2015; 68(3): 264-73. 
219. Naranbhai V, Altfeld M, Abdool Karim Q, et al. Natural killer cell function in women 
at high risk for HIV acquisition: insights from a microbicide trial. AIDS 2012; 26(14): 1745-
53. 
220. Ghadially H, Keynan Y, Kimani J, et al. Altered dendritic cell-natural killer interaction 
in Kenyan sex workers resistant to HIV-1 infection. AIDS 2012; 26(4): 429-36. 
221. McLaren PJ, Carrington M. The impact of host genetic variation on infection with 
HIV-1. Nature immunology 2015; 16(6): 577-83. 
  58
222. Naranbhai V, Abdool Karim SS, Altfeld M, et al. Innate immune activation enhances 
hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. The 
Journal of infectious diseases 2012; 206(7): 993-1001. 
223. Koehler RN, Alter G, Tovanabutra S, et al. Natural Killer Cell-Mediated Innate Sieve 
Effect on HIV-1: The Impact of KIR/HLA Polymorphism on HIV-1 Subtype-Specific 
Acquisition in East Africa. The Journal of infectious diseases 2013; 208(8): 1250-4. 
224. Vargas-Inchaustegui DA, Xiao P, Tuero I, Patterson LJ, Robert-Guroff M. NK and 
CD4+ T cell cooperative immune responses correlate with control of disease in a macaque 
simian immunodeficiency virus infection model. Journal of immunology 2012; 189(4): 1878-
85. 
225. Pollara J, Bonsignori M, Moody MA, et al. HIV-1 vaccine-induced C1 and V2 Env-
specific antibodies synergize for increased antiviral activities. Journal of virology 2014; 
88(14): 7715-26. 
226. Tomaras GD, Ferrari G, Shen X, et al. Vaccine-induced plasma IgA specific for the C1 
region of the HIV-1 envelope blocks binding and effector function of IgG. Proceedings of the 
National Academy of Sciences of the United States of America 2013; 110(22): 9019-24. 
227. Milligan C, Richardson BA, John-Stewart G, Nduati R, Overbaugh J. Passively 
acquired antibody-dependent cellular cytotoxicity (ADCC) activity in HIV-infected infants is 
associated with reduced mortality. Cell host & microbe 2015; 17(4): 500-6. 
228. Della Chiesa M, Marcenaro E, Sivori S, Carlomagno S, Pesce S, Moretta A. Human 
NK cell response to pathogens. Seminars in immunology 2014; 26(2): 152-60. 
229. Jost S, Altfeld M. Evasion from NK cell-mediated immune responses by HIV-1. 
Microbes and infection / Institut Pasteur 2012; 14(11): 904-15. 
230. Iannello A, Debbeche O, Samarani S, Ahmad A. Antiviral NK cell responses in HIV 
infection: II. viral strategies for evasion and lessons for immunotherapy and vaccination. 
Journal of leukocyte biology 2008; 84(1): 27-49. 
231. van Teijlingen NH, Holzemer A, Korner C, et al. Sequence variations in HIV-1 p24 
Gag-derived epitopes can alter binding of KIR2DL2 to HLA-C*03:04 and modulate primary 
natural killer cell function. AIDS 2014; 28(10): 1399-408. 
232. Bolduan S, Reif T, Schindler M, Schubert U. HIV-1 Vpu mediated downregulation of 
CD155 requires alanine residues 10, 14 and 18 of the transmembrane domain. Virology 2014; 
464-465: 375-84. 
233. Marras F, Nicco E, Bozzano F, et al. Natural killer cells in HIV controller patients 
express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation. 
Proceedings of the National Academy of Sciences of the United States of America 2013. 
234. Naranbhai V, Altfeld M, Karim SS, Ndung'u T, Karim QA, Carr WH. Changes in 
Natural Killer cell activation and function during primary HIV-1 Infection. PloS one 2013; 
8(1): e53251. 
235. Luteijn R, Sciaranghella G, van Lunzen J, et al. Early viral replication in lymph nodes 
provides HIV with a means by which to escape NK-cell-mediated control. Eur J Immunol 
2011; 41(9): 2729-40. 
236. Matusali G, Potesta M, Santoni A, Cerboni C, Doria M. The human immunodeficiency 
virus type 1 Nef and Vpu proteins downregulate the natural killer cell-activating ligand PVR. 
Journal of virology 2012; 86(8): 4496-504. 
   59
237. Melki MT, Saidi H, Dufour A, Olivo-Marin JC, Gougeon ML. Escape of HIV-1-
infected dendritic cells from TRAIL-mediated NK cell cytotoxicity during NK-DC cross-
talk--a pivotal role of HMGB1. PLoS pathogens 2010; 6(4): e1000862. 
238. Gougeon ML, Bras M. Natural killer cells, dendritic cells, and the alarmin high-
mobility group box 1 protein: a dangerous trio in HIV-1 infection? Current opinion in HIV 
and AIDS 2011; 6(5): 364-72. 
239. Dillon SM, Lee EJ, Bramante JM, Barker E, Wilson CC. The natural killer cell 
interferon-gamma response to bacteria is diminished in untreated HIV-1 infection and defects 
persist despite viral suppression. Journal of acquired immune deficiency syndromes 2014; 
65(3): 259-67. 
240. Arias JF, Heyer LN, von Bredow B, et al. Tetherin antagonism by Vpu protects HIV-
infected cells from antibody-dependent cell-mediated cytotoxicity. Proceedings of the 
National Academy of Sciences 2014; 111(17): 6425-30. 
241. Alvarez RA, Hamlin RE, Monroe A, et al. HIV-1 Vpu Antagonism of Tetherin Inhibits 
Antibody-Dependent Cellular Cytotoxic Responses by Natural Killer Cells. Journal of 
virology 2014; 88(11): 6031-46. 
242. Goodier MR, Imami N, Moyle G, Gazzard B, Gotch F. Loss of the CD56hiCD16- NK 
cell subset and NK cell interferon-gamma production during antiretroviral therapy for HIV-1: 
partial recovery by human growth hormone. Clinical and experimental immunology 2003; 
134(3): 470-6. 
243. Brunetta E, Hudspeth KL, Mavilio D. Pathologic natural killer cell subset redistribution 
in HIV-1 infection: new insights in pathophysiology and clinical outcomes. Journal of 
leukocyte biology 2010; 88(6): 1119-30. 
244. Ellegard R, Crisci E, Andersson J, et al. Impaired NK Cell Activation and Chemotaxis 
toward Dendritic Cells Exposed to Complement-Opsonized HIV-1. Journal of immunology 
2015; 195(4): 1698-704. 
245. Blish CA, Dogan OC, Jaoko W, et al. Association between cellular immune activation, 
target cell frequency, and risk of human immunodeficiency virus type 1 superinfection. 
Journal of virology 2014; 88(10): 5894-9. 
246. Gupta S, Gach JS, Becerra JC, et al. The Neonatal Fc receptor (FcRn) enhances human 
immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells. PLoS pathogens 
2013; 9(11): e1003776. 
247. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and 
CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA 
levels in the absence of therapy. The Journal of infectious diseases 2008; 197(1): 126-33. 
248. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV. Elevated CD38 
antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease 
progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, 
soluble immune activation markers, or combinations of HLA-DR and CD38 expression. 
Journal of acquired immune deficiency syndromes and human retrovirology : official 
publication of the International Retrovirology Association 1997; 16(2): 83-92. 
249. Paiardini M, Muller-Trutwin M. HIV-associated chronic immune activation. 
Immunological reviews 2013; 254(1): 78-101. 
  60
250. Wu L, LaRosa G, Kassam N, et al. Interaction of chemokine receptor CCR5 with its 
ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine 
binding. The Journal of experimental medicine 1997; 186(8): 1373-81. 
251. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA 
cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272(5263): 
872-7. 
252. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during 
chronic HIV infection. Immunity 2013; 39(4): 633-45. 
253. Dillon SM, Lee EJ, Kotter CV, et al. An altered intestinal mucosal microbiome in HIV-
1 infection is associated with mucosal and systemic immune activation and endotoxemia. 
Mucosal immunology 2014; 7(4): 983-94. 
254. Breed MW, Jordan APO, Aye PP, et al. Loss of a Tyrosine-Dependent Trafficking 
Motif in the Simian Immunodeficiency Virus Envelope Cytoplasmic Tail Spares Mucosal 
CD4 Cells but Does Not Prevent Disease Progression. Journal of virology 2013; 87(3): 1528-
43. 
255. Lin L, Finak G, Ushey K, et al. COMPASS identifies T-cell subsets correlated with 
clinical outcomes. Nature biotechnology 2015; 33(6): 610-6. 
256. Eller MA, Goonetilleke N, Tassaneetrithep B, et al. Expansion of Inefficient HIV-
Specific CD8 T Cells during Acute Infection. Journal of virology 2016; 90(8): 4005-16. 
257. Leviyang S, Ganusov VV. Broad CTL Response in Early HIV Infection Drives 
Multiple Concurrent CTL Escapes. PLoS computational biology 2015; 11(10): e1004492. 
258. Deng K, Pertea M, Rongvaux A, et al. Broad CTL response is required to clear latent 
HIV-1 due to dominance of escape mutations. Nature 2015; 517(7534): 381-5. 
259. Allen TM, Yu XG, Kalife ET, et al. De Novo Generation of Escape Variant-Specific 
CD8+ T-Cell Responses following Cytotoxic T-Lymphocyte Escape in Chronic Human 
Immunodeficiency Virus Type 1 Infection. Journal of virology 2005; 79(20): 12952-60. 
260. Liu MK, Hawkins N, Ritchie AJ, et al. Vertical T cell immunodominance and epitope 
entropy determine HIV-1 escape. The Journal of clinical investigation 2013; 123(1): 380-93. 
261. Koup RA. Virus escape from CTL recognition. The Journal of experimental medicine 
1994; 180(3): 779-82. 
262. Doisne JM, Urrutia A, Lacabaratz-Porret C, et al. CD8+ T cells specific for EBV, 
cytomegalovirus, and influenza virus are activated during primary HIV infection. Journal of 
immunology 2004; 173(4): 2410-8. 
263. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain 
highly functional HIV-specific CD8+ T cells. Blood 2006; 107(12): 4781-9. 
264. Graw F, Regoes RR. Predicting the impact of CD8+ T cell polyfunctionality on HIV 
disease progression. Journal of virology 2014; 88(17): 10134-45. 
265. Chang C-H, Kist NC, Chester TLS, et al. HIV-infected sex workers with beneficial 
HLA-variants are potential hubs for selection of HIV-1 recombinants that may affect disease 
progression. Scientific Reports 2015; 5: 11253. 
266. Hua S, Lecuroux C, Saez-Cirion A, et al. Potential role for HIV-specific CD38-/HLA-
DR+ CD8+ T cells in viral suppression and cytotoxicity in HIV controllers. PloS one 2014; 
9(7): e101920. 
   61
267. Payne TL, Blackinton J, Frisbee A, et al. Transcriptional and posttranscriptional 
regulation of cytokine gene expression in HIV-1 antigen-specific CD8+ T cells that mediate 
virus inhibition. Journal of virology 2014; 88(17): 9514-28. 
268. Yan J, Sabbaj S, Bansal A, et al. HIV-Specific CD8+ T Cells from Elite Controllers 
Are Primed for Survival. Journal of virology 2013; 87(9): 5170-81. 
269. Breed MW, Elser SE, Torben W, et al. Elite Control, Gut CD4 T Cell Sparing, and 
Enhanced Mucosal T Cell Responses in Macaca nemestrina Infected by a Simian 
Immunodeficiency Virus Lacking a gp41 Trafficking Motif. Journal of virology 2015; 
89(20): 10156-75. 
270. Sforza F, Nicoli F, Gallerani E, et al. HIV-1 Tat affects the programming and 
functionality of human CD8(+) T cells by modulating the expression of T-box transcription 
factors. AIDS 2014; 28(12): 1729-38. 
271. Pion M, Jaramillo-Ruiz D, Martinez A, Munoz-Fernandez MA, Correa-Rocha R. HIV 
infection of human regulatory T cells downregulates Foxp3 expression by increasing 
DNMT3b levels and DNA methylation in the FOXP3 gene. AIDS 2013; 27(13): 2019-29. 
272. Mendez-Lagares G, Jaramillo-Ruiz D, Pion M, et al. HIV infection deregulates the 
balance between regulatory T cells and IL-2-producing CD4 T cells by decreasing the 
expression of the IL-2 receptor in Treg. Journal of acquired immune deficiency syndromes 
2014; 65(3): 278-82. 
273. Chevalier MF, Weiss L. The split personality of regulatory T cells in HIV infection. 
Blood 2013; 121(1): 29-37. 
274. Angin M, Klarenbeek PL, King M, et al. Regulatory T cells expanded from HIV-1-
infected individuals maintain phenotype, TCR repertoire and suppressive capacity. PloS one 
2014; 9(2): e86920. 
275. Angin M, Sharma S, King M, et al. HIV-1 infection impairs regulatory T-cell 
suppressive capacity on a per-cell basis. The Journal of infectious diseases 2014; 210(6): 
899-903. 
276. Kwon DS, Angin M, Hongo T, et al. CD4+ CD25+ regulatory T cells impair HIV-1-
specific CD4 T cell responses by upregulating interleukin-10 production in monocytes. 
Journal of virology 2012; 86(12): 6586-94. 
277. Peligero C, Argilaguet J, Guerri-Fernandez R, et al. PD-L1 Blockade Differentially 
Impacts Regulatory T Cells from HIV-Infected Individuals Depending on Plasma Viremia. 
PLoS pathogens 2015; 11(12): e1005270. 
278. Rout N, Greene J, Yue S, et al. Loss of effector and anti-inflammatory natural killer T 
lymphocyte function in pathogenic simian immunodeficiency virus infection. PLoS 
pathogens 2012; 8(9): e1002928. 
279. Chen N, McCarthy C, Drakesmith H, et al. HIV-1 down-regulates the expression of 
CD1d via Nef. Eur J Immunol 2006; 36(2): 278-86. 
280. Cho S, Knox KS, Kohli LM, et al. Impaired cell surface expression of human CD1d by 
the formation of an HIV-1 Nef/CD1d complex. Virology 2005; 337(2): 242-52. 
281. Moll M, Andersson SK, Smed-Sorensen A, Sandberg JK. Inhibition of lipid antigen 
presentation in dendritic cells by HIV-1 Vpu interference with CD1d recycling from 
endosomal compartments. Blood 2010; 116(11): 1876-84. 
  62
282. Paquin-Proulx D, Gibbs A, Bachle SM, et al. Innate Invariant NKT Cell Recognition of 
HIV-1-Infected Dendritic Cells Is an Early Detection Mechanism Targeted by Viral Immune 
Evasion. Journal of immunology 2016; 197(5): 1843-51. 
283. Nasi M, Pinti M, Mussini C, Cossarizza A. Persistent inflammation in HIV infection: 
established concepts, new perspectives. Immunology letters 2014; 161(2): 184-8. 
284. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human 
immunodeficiency virus type 1 infection is more closely associated with T lymphocyte 
activation than with plasma virus burden or virus chemokine coreceptor usage. The Journal 
of infectious diseases 1999; 179(4): 859-70. 
285. Giorgi JV, Detels R. T-cell subset alterations in HIV-infected homosexual men: NIAID 
Multicenter AIDS cohort study. Clinical immunology and immunopathology 1989; 52(1): 10-
8. 
286. Deeks SG, Kitchen CM, Liu L, et al. Immune activation set point during early HIV 
infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 2004; 
104(4): 942-7. 
287. Boasso A, Hardy AW, Landay AL, et al. PDL-1 upregulation on monocytes and T cells 
by HIV via type I interferon: restricted expression of type I interferon receptor by CCR5-
expressing leukocytes. Clinical immunology 2008; 129(1): 132-44. 
288. Moll M, Kuylenstierna C, Gonzalez VD, et al. Severe functional impairment and 
elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 
infection. Eur J Immunol 2009; 39(3): 902-11. 
289. Jones RB, Ndhlovu LC, Barbour JD, et al. Tim-3 expression defines a novel population 
of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. The 
Journal of experimental medicine 2008; 205(12): 2763-79. 
290. Wherry EJ. T cell exhaustion. Nature immunology 2011; 12(6): 492-9. 
291. Kuchroo VK, Anderson AC, Petrovas C. Coinhibitory receptors and CD8 T cell 
exhaustion in chronic infections. Current opinion in HIV and AIDS 2014; 9(5): 439-45. 
292. Hasley RB, Hong C, Li W, et al. HIV immune activation drives increased Eomes 
expression in memory CD8 T cells in association with transcriptional downregulation of 
CD127. AIDS 2013; 27(12): 1867-77. 
293. Neuhaus J, Jacobs DR, Jr., Baker JV, et al. Markers of inflammation, coagulation, and 
renal function are elevated in adults with HIV infection. The Journal of infectious diseases 
2010; 201(12): 1788-95. 
294. Trautmann L, Mbitikon-Kobo FM, Goulet JP, et al. Profound metabolic, functional, 
and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV 
infection. Blood 2012; 120(17): 3466-77. 
295. Espert L, Denizot M, Grimaldi M, et al. Autophagy is involved in T cell death after 
binding of HIV-1 envelope proteins to CXCR4. The Journal of clinical investigation 2006; 
116(8): 2161-72. 
296. Trinite B, Chan CN, Lee CS, Levy DN. HIV-1 Vpr- and Reverse Transcription-
Induced Apoptosis in Resting Peripheral Blood CD4 T Cells and Protection by Common 
Gamma-Chain Cytokines. Journal of virology 2016; 90(2): 904-16. 
   63
297. Breton G, Chomont N, Takata H, et al. Programmed Death-1 Is a Marker for Abnormal 
Distribution of Naive/Memory T Cell Subsets in HIV-1 Infection. Journal of immunology 
2013. 
298. Paris RM, Petrovas C, Ferrando-Martinez S, et al. Selective Loss of Early 
Differentiated, Highly Functional PD1high CD4 T Cells with HIV Progression. PloS one 
2015; 10(12): e0144767. 
299. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annual review 
of medicine 2011; 62: 141-55. 
300. Tsoukas C. Immunosenescence and aging in HIV. Current opinion in HIV and AIDS 
2014; 9(4): 398-404. 
301. Kiwanuka N, Laeyendecker O, Robb M, et al. Effect of human immunodeficiency virus 
Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident 
HIV-1 infection. The Journal of infectious diseases 2008; 197(5): 707-13. 
302. Olemukan RE, Eller LA, Ouma BJ, et al. Quality monitoring of HIV-1-infected and 
uninfected peripheral blood mononuclear cell samples in a resource-limited setting. Clinical 
and vaccine immunology : CVI 2010; 17(6): 910-8. 
303. Dominguez MH, Chattopadhyay PK, Ma S, et al. Highly multiplexed quantitation of 
gene expression on single cells. Journal of immunological methods 2013; 391(1-2): 133-45. 
304. Villacres MC, Longmate J, Auge C, Diamond DJ. Predominant type 1 CMV-specific 
memory T-helper response in humans: evidence for gender differences in cytokine secretion. 
Human immunology 2004; 65(5): 476-85. 
305. Berghofer B, Frommer T, Haley G, Fink L, Bein G, Hackstein H. TLR7 ligands induce 
higher IFN-alpha production in females. Journal of immunology 2006; 177(4): 2088-96. 
306. Torcia MG, Nencioni L, Clemente AM, et al. Sex differences in the response to viral 
infections: TLR8 and TLR9 ligand stimulation induce higher IL10 production in males. PloS 
one 2012; 7(6): e39853. 
307. Hewagama A, Patel D, Yarlagadda S, Strickland FM, Richardson BC. Stronger 
inflammatory/cytotoxic T-cell response in women identified by microarray analysis. Genes 
and immunity 2009; 10(5): 509-16. 
308. Klein SL. Sex influences immune responses to viruses, and efficacy of prophylaxis and 
treatments for viral diseases. BioEssays : news and reviews in molecular, cellular and 
developmental biology 2012; 34(12): 1050-9. 
309. Collazos J, Asensi V, Carton JA. Sex differences in the clinical, immunological and 
virological parameters of HIV-infected patients treated with HAART. AIDS 2007; 21(7): 
835-43. 
310. Chow WZ, Lim SH, Ong LY, et al. Impact of HIV-1 Subtype on the Time to CD4+ T-
Cell Recovery in Combination Antiretroviral Therapy (cART)-Experienced Patients. PloS 
one 2015; 10(9): e0137281. 
311. Siddiqui RA, Sauermann U, Altmuller J, et al. X chromosomal variation is associated 
with slow progression to AIDS in HIV-1-infected women. American journal of human 
genetics 2009; 85(2): 228-39. 
312. Krebs SJ, Slike BM, Sithinamsuwan P, et al. Sex differences in soluble markers vary 
before and after the initiation of antiretroviral therapy in chronically HIV-infected 
individuals. AIDS 2016; 30(10): 1533-42. 
  64
313. Lemly DC, Shepherd BE, Hulgan T, et al. Race and sex differences in antiretroviral 
therapy use and mortality among HIV-infected persons in care. The Journal of infectious 
diseases 2009; 199(7): 991-8. 
314. Farzadegan H, Hoover DR, Astemborski J, et al. Sex differences in HIV-1 viral load 
and progression to AIDS. Lancet (London, England) 1998; 352(9139): 1510-4. 
315. Zhang L, Wang Z, Chen Y, et al. Label-free proteomic analysis of PBMCs reveals 
gender differences in response to long-term antiretroviral therapy of HIV. Journal of 
proteomics 2015; 126: 46-53. 
316. Mathad JS, Gupte N, Balagopal A, et al. Sex-Related Differences in Inflammatory and 
Immune Activation Markers Before and After Combined Antiretroviral Therapy Initiation. 
Journal of acquired immune deficiency syndromes 2016; 73(2): 123-9. 
317. Fish EN. The X-files in immunity: sex-based differences predispose immune responses. 
Nature reviews Immunology 2008; 8(9): 737-44. 
318. Weinberg A, Enomoto L, Marcus R, Canniff J. Effect of menstrual cycle variation in 
female sex hormones on cellular immunity and regulation. Journal of reproductive 
immunology 2011; 89(1): 70-7. 
319. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in 
pharmacokinetics and pharmacodynamics. Annual review of pharmacology and toxicology 
2004; 44: 499-523. 
320. Suurmond J, Stoop JN, Rivellese F, Bakker AM, Huizinga TW, Toes RE. Activation of 
human basophils by combined toll-like receptor- and FcepsilonRI-triggering can promote 
Th2 skewing of naive T helper cells. Eur J Immunol 2014; 44(2): 386-96. 
321. Ziegler S, Altfeld M. Sex differences in HIV-1-mediated immunopathology. Current 
opinion in HIV and AIDS 2016; 11(2): 209-15. 
322. Karasuyama H, Yamanishi Y. Basophils have emerged as a key player in immunity. 
Current opinion in immunology 2014; 31C: 1-7. 
323. Geering B, Stoeckle C, Conus S, Simon HU. Living and dying for inflammation: 
neutrophils, eosinophils, basophils. Trends in immunology 2013; 34(8): 398-409. 
324. Mauvais-Jarvis F. Sex differences in metabolic homeostasis, diabetes, and obesity. 
Biology of sex differences 2015; 6: 14. 
325. Meier A, Chang JJ, Chan ES, et al. Sex differences in the Toll-like receptor-mediated 
response of plasmacytoid dendritic cells to HIV-1. Nat Med 2009; 15(8): 955-9. 
326. Chang JJ, Woods M, Lindsay RJ, et al. Higher expression of several interferon-
stimulated genes in HIV-1-infected females after adjusting for the level of viral replication. 
The Journal of infectious diseases 2013; 208(5): 830-8. 
327. Le Chenadec J, Scott-Algara D, Blanche S, et al. Gag-Specific CD4 and CD8 T-Cell 
Proliferation in Adolescents and Young Adults with Perinatally Acquired HIV-1 Infection Is 
Associated with Ethnicity - The ANRS-EP38-IMMIP Study. PloS one 2015; 10(12): 
e0144706. 
328. Scott-Algara D, Warszawski J, Le Chenadec J, et al. Gag-Specific CD4 T Cell 
Proliferation, Plasmacytoid Dendritic Cells, and Ethnicity in Perinatally HIV-1-Infected 
Youths: The ANRS-EP38-IMMIP Study. AIDS research and human retroviruses 2016. 
   65
329. Karita E, Ketter N, Price MA, et al. CLSI-derived hematology and biochemistry 
reference intervals for healthy adults in eastern and southern Africa. PloS one 2009; 4(2): 
e4401. 
330. Wu X, Zhao M, Pan B, et al. Complete Blood Count Reference Intervals for Healthy 
Han Chinese Adults. PloS one 2015; 10(3): e0119669. 
331. Pang Y, Kang W, Zhao A, et al. The effect of bacille Calmette-Guerin vaccination at 
birth on immune response in China. Vaccine 2015; 33(1): 209-13. 
332. Serre Delcor N, Maruri BT, Arandes AS, et al. Infectious Diseases in Sub-Saharan 
Immigrants to Spain. The American journal of tropical medicine and hygiene 2016; 94(4): 
750-6. 
333. Rawat R, McCoy SI, Kadiyala S. Poor diet quality is associated with low CD4 count 
and anemia and predicts mortality among antiretroviral therapy-naive HIV-positive adults in 
Uganda. Journal of acquired immune deficiency syndromes 2013; 62(2): 246-53. 
334. Chin YT, Lim YA, Chong CW, et al. Prevalence and risk factors of intestinal 
parasitism among two indigenous sub-ethnic groups in Peninsular Malaysia. Infectious 
diseases of poverty 2016; 5(1): 77. 
335. Arnold AP, Lusis AJ. Understanding the sexome: measuring and reporting sex 
differences in gene systems. Endocrinology 2012; 153(6): 2551-5. 
336. Johnston RE, Heitzeg MM. Sex, age, race and intervention type in clinical studies of 
HIV cure: a systematic review. AIDS research and human retroviruses 2015; 31(1): 85-97. 
337. CLSI. Defining, Establishing, and Verifying Reference Intervals in the Clinical 
Laboratory; Approved guideline - third edition. Wayne, PA: Clinical and Laboratory 
Standards Institute; 2008. 
338. Ren W, Ma Y, Yang L, et al. Fast disease progression in simian HIV-infected female 
macaque is accompanied by a robust local inflammatory innate immune and microbial 
response. AIDS 2015; 29(10): F1-8. 
339. Roff SR, Noon-Song EN, Yamamoto JK. The Significance of Interferon-gamma in 
HIV-1 Pathogenesis, Therapy, and Prophylaxis. Frontiers in immunology 2014; 4: 498. 
340. Bonnema JD, Rivlin KA, Ting AT, Schoon RA, Abraham RT, Leibson PJ. Cytokine-
enhanced NK cell-mediated cytotoxicity. Positive modulatory effects of IL-2 and IL-12 on 
stimulus-dependent granule exocytosis. Journal of immunology 1994; 152(5): 2098-104. 
341. Hashimoto W, Osaki T, Okamura H, et al. Differential antitumor effects of 
administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas 
ligand- and perforin-induced tumor apoptosis, respectively. Journal of immunology 1999; 
163(2): 583-9. 
342. Kyei SK, Ogbomo H, Li S, et al. Mechanisms by Which Interleukin-12 Corrects 
Defective NK Cell Anticryptococcal Activity in HIV-Infected Patients. mBio 2016; 7(4). 
343. Schmidt S, Tramsen L, Hanisch M, et al. Human natural killer cells exhibit direct 
activity against Aspergillus fumigatus hyphae, but not against resting conidia. The Journal of 
infectious diseases 2011; 203(3): 430-5. 
344. Schmidt S, Zimmermann SY, Tramsen L, Koehl U, Lehrnbecher T. Natural killer cells 
and antifungal host response. Clinical and vaccine immunology : CVI 2013; 20(4): 452-8. 
  66
345. Parkes-Ratanshi R, Achan B, Kwizera R, Kambugu A, Meya D, Denning DW. 
Cryptococcal disease and the burden of other fungal diseases in Uganda; Where are the 
knowledge gaps and how can we fill them? Mycoses 2015; 58 Suppl 5: 85-93. 
346. Haddow LJ, Colebunders R, Meintjes G, et al. Cryptococcal immune reconstitution 
inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. 
The Lancet infectious diseases 2010; 10(11): 791-802. 
347. Meya DB, Okurut S, Zziwa G, et al. Cellular immune activation in cerebrospinal fluid 
from ugandans with cryptococcal meningitis and immune reconstitution inflammatory 
syndrome. The Journal of infectious diseases 2015; 211(10): 1597-606. 
348. Boulware DR, Meya DB, Bergemann TL, et al. Clinical features and serum biomarkers 
in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a 
prospective cohort study. PLoS medicine 2010; 7(12): e1000384. 
349. Tan HY, Yong YK, Shankar EM, et al. Aberrant Inflammasome Activation 
Characterizes Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. 
Journal of immunology 2016; 196(10): 4052-63. 
350. Della Chiesa M, Falco M, Podesta M, et al. Phenotypic and functional heterogeneity of 
human NK cells developing after umbilical cord blood transplantation: a role for human 
cytomegalovirus? Blood 2012; 119(2): 399-410. 
351. Lunemann S, Malone DF, Hengst J, et al. Compromised function of natural killer cells 
in acute and chronic viral hepatitis. The Journal of infectious diseases 2014; 209(9): 1362-73. 
352. Sereti I, Krebs SJ, Phanuphak N, et al. Initiation of antiretroviral therapy in early HIV 
infection reduces but does not abrogate chronic residual inflammation. Clinical infectious 
diseases : an official publication of the Infectious Diseases Society of America 2016. 
353. Amu S, Lantto Graham R, Bekele Y, et al. Dysfunctional phenotypes of CD4+ and 
CD8+ T cells are comparable in patients initiating ART during early or chronic HIV-1 
infection. Medicine 2016; 95(23): e3738. 
354. Finney CA, Ayi K, Wasmuth JD, et al. HIV infection deregulates innate immunity to 
malaria despite combination antiretroviral therapy. AIDS 2013; 27(3): 325-35. 
355. Redd AD, Eaton KP, Kong X, et al. C-reactive protein levels increase during HIV-1 
disease progression in Rakai, Uganda, despite the absence of microbial translocation. Journal 
of acquired immune deficiency syndromes 2010; 54(5): 556-9. 
356. Utay NS, Hunt PW. Role of immune activation in progression to AIDS. Current 
opinion in HIV and AIDS 2016; 11(2): 131-7. 
357. Nixon DE, Landay AL. Biomarkers of immune dysfunction in HIV. Current opinion in 
HIV and AIDS 2010; 5(6): 498-503. 
358. Sandler NG, Sereti I. Can early therapy reduce inflammation? Current opinion in HIV 
and AIDS 2014; 9(1): 72-9. 
359. Zevin AS, McKinnon L, Burgener A, Klatt NR. Microbial translocation and 
microbiome dysbiosis in HIV-associated immune activation. Current opinion in HIV and 
AIDS 2016; 11(2): 182-90. 
360. Greenwood Z, Black J, Weld L, et al. Gastrointestinal infection among international 
travelers globally. Journal of travel medicine 2008; 15(4): 221-8. 
   67
361. Cliffe LJ, Humphreys NE, Lane TE, Potten CS, Booth C, Grencis RK. Accelerated 
intestinal epithelial cell turnover: a new mechanism of parasite expulsion. Science 2005; 
308(5727): 1463-5. 
362. Karagiannis-Voules DA, Biedermann P, Ekpo UF, et al. Spatial and temporal 
distribution of soil-transmitted helminth infection in sub-Saharan Africa: a systematic review 
and geostatistical meta-analysis. The Lancet infectious diseases 2015; 15(1): 74-84. 
363. Redd AD, Dabitao D, Bream JH, et al. Microbial translocation, the innate cytokine 
response, and HIV-1 disease progression in Africa. Proceedings of the National Academy of 
Sciences of the United States of America 2009; 106(16): 6718-23. 
364. Boulougoura A, Sereti I. HIV infection and immune activation: the role of coinfections. 
Current opinion in HIV and AIDS 2016; 11(2): 191-200. 
365. Sandberg JK, Fast NM, Palacios EH, et al. Selective loss of innate CD4(+) V alpha 24 
natural killer T cells in human immunodeficiency virus infection. Journal of virology 2002; 
76(15): 7528-34. 
366. Bachle SM, Malone DF, Buggert M, et al. Elevated levels of invariant natural killer T-
cell and natural killer cell activation correlate with disease progression in HIV-1 and HIV-2 
infections. AIDS 2016; 30(11): 1713-22. 
367. Boaz MJ, Waters A, Murad S, Easterbrook PJ, Vyakarnam A. Presence of HIV-1 Gag-
specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with 
nonprogression in HIV-1 infection. Journal of immunology 2002; 169(11): 6376-85. 
368. Jost S, Tomezsko PJ, Rands K, et al. CD4+ T-cell help enhances NK cell function 
following therapeutic HIV-1 vaccination. Journal of virology 2014; 88(15): 8349-54. 
369. Pollock KM, Montamat-Sicotte DJ, Grass L, et al. PD-1 Expression and Cytokine 
Secretion Profiles of Mycobacterium tuberculosis-Specific CD4+ T-Cell Subsets; Potential 
Correlates of Containment in HIV-TB Co-Infection. PloS one 2016; 11(1): e0146905. 
370. Bjorkstrom NK, Gonzalez VD, Malmberg KJ, et al. Elevated numbers of Fc gamma 
RIIIA+ (CD16+) effector CD8 T cells with NK cell-like function in chronic hepatitis C virus 
infection. Journal of immunology 2008; 181(6): 4219-28. 
371. Chu T, Tyznik AJ, Roepke S, et al. Bystander-activated memory CD8 T cells control 
early pathogen load in an innate-like, NKG2D-dependent manner. Cell Rep 2013; 3(3): 701-
8. 
372. Soudja SM, Ruiz AL, Marie JC, Lauvau G. Inflammatory monocytes activate memory 
CD8(+) T and innate NK lymphocytes independent of cognate antigen during microbial 
pathogen invasion. Immunity 2012; 37(3): 549-62. 
373. Kastenmuller W, Torabi-Parizi P, Subramanian N, Lammermann T, Germain RN. A 
spatially-organized multicellular innate immune response in lymph nodes limits systemic 
pathogen spread. Cell 2012; 150(6): 1235-48. 
374. Jacomet F, Cayssials E, Basbous S, et al. Evidence for eomesodermin-expressing 
innate-like CD8(+) KIR/NKG2A(+) T cells in human adults and cord blood samples. Eur J 
Immunol 2015; 45(7): 1926-33. 
375. Knox JJ, Cosma GL, Betts MR, McLane LM. Characterization of T-Bet and Eomes in 
Peripheral Human Immune Cells. Frontiers in immunology 2014; 5: 217. 
376. Alter G, Heckerman D, Schneidewind A, et al. HIV-1 adaptation to NK-cell-mediated 
immune pressure. Nature 2011; 476(7358): 96-100. 
  68
377. Bjorkstrom NK, Beziat V, Cichocki F, et al. CD8 T cells express randomly selected 
KIRs with distinct specificities compared with NK cells. Blood 2012; 120(17): 3455-65. 
378. Williams LD, Bansal A, Sabbaj S, et al. Interleukin-21-producing HIV-1-specific CD8 
T cells are preferentially seen in elite controllers. Journal of virology 2011; 85(5): 2316-24. 
379. White L, Krishnan S, Strbo N, et al. Differential effects of IL-21 and IL-15 on perforin 
expression, lysosomal degranulation, and proliferation in CD8 T cells of patients with human 
immunodeficiency virus-1 (HIV). Blood 2007; 109(9): 3873-80. 
380. Freud AG, Keller KA, Scoville SD, et al. NKp80 Defines a Critical Step during Human 
Natural Killer Cell Development. Cell Rep 2016; 16(2): 379-91. 
381. Welte S, Kuttruff S, Waldhauer I, Steinle A. Mutual activation of natural killer cells 
and monocytes mediated by NKp80-AICL interaction. Nature immunology 2006; 7(12): 
1334-42. 
382. Akimova T, Beier UH, Wang L, Levine MH, Hancock WW. Helios expression is a 
marker of T cell activation and proliferation. PloS one 2011; 6(8): e24226. 
383. Fuertes Marraco SA, Soneson C, Delorenzi M, Speiser DE. Genome-wide RNA 
profiling of long-lasting stem cell-like memory CD8 T cells induced by Yellow Fever 
vaccination in humans. Genomics Data 2015; 5: 297-301. 
384. Blom K, Braun M, Ivarsson MA, et al. Temporal dynamics of the primary human T 
cell response to yellow fever virus 17D as it matures from an effector- to a memory-type 
response. Journal of immunology 2013; 190(5): 2150-8. 
 
 
